The Treatment Tapes, home

The AtlasProteins

Tyrosine kinases

About ninety enzymes that pass growth signals on by tagging proteins at tyrosine, found by accident in 1979, jammed on in leukemias and lung cancers, and the target of the drug class that proved a pill could switch a cancer off, then had to learn when it could be stopped and what it cost the heart.

Status Reference · not yet an episodeSources 148Reviewed 30 Oct 2026
What it is
A family of enzymes that move phosphate from ATP onto tyrosine in proteins; the phosphotyrosine becomes a docking site for other signaling proteins 1,2
How many
90 human genes and five pseudogenes: 58 receptor, in 20 subfamilies, and 32 non-receptor, in 10 3; four of the receptors were predicted to have no working kinase 4, though ERBB3 was later shown to keep a weak one 5. The whole human kinome was counted at 518 genes in 2002 6
Basic structure
A catalytic domain of about 260 amino acids; receptor types add an outside binding domain and one membrane-crossing segment, non-receptor types add domains such as SH2, which reads phosphotyrosine, and SH3, which binds proline-rich stretches of other proteins 4,7,8
Size
Examples, not limits: pp60src is named for its roughly 60-kilodalton size, the insulin receptor precursor is 1,370 amino acids, and the leukemic fusion BCR-ABL is about 210 kilodaltons 9,10,11
Genes and chromosomes
Scattered: ABL1 on chromosome 9 and its fusion partner BCR on 22, JAK2 on 9p, RET on 10q11.2, FGFR3 on 4p16.3, ALK on 2p, BTK on the X chromosome 11,12,13,14,15,16,17
Discovered
Summer 1979, as kinase activity bound to the cancer proteins of polyomavirus and then of Rous sarcoma virus 4,9,18
How rare the mark is
Phosphotyrosine is under 1% of the phosphate attached to proteins; the rest is on serine and threonine 4
In cancer
51 of the 90 implicated through mutation or abnormal amounts 4
First inhibitor approved
Imatinib, the first selective tyrosine kinase inhibitor approved for a cancer, chronic myeloid leukemia, on 10 May 2001; 10-year overall survival 83.3% in its pivotal trial 4,19,20
Approved drugs now
94 US-approved kinase inhibitors in 2026, 48 aimed at receptor and 26 at non-receptor tyrosine kinases; ten approved in 2025 21
Biggest safety reversal
ORAL Surveillance: tofacitinib, a JAK inhibitor, failed to prove itself as safe as tumor necrosis factor (TNF) inhibitors, injected biologic drugs, for heart events and cancer in 4,362 older patients with rheumatoid arthritis 22
Biggest treatment reversal
Chronic myeloid leukemia treatment is no longer necessarily for life: about half of patients in deep remission stay in remission after stopping 23,24

In brief

What it is

Tyrosine kinases are a family rather than a single protein: about 90 human enzymes, 58 built into the cell surface as receptors and 32 working inside the cell 3. Each carries a catalytic domain of about 260 amino acids that moves a phosphate group from ATP, the cell's energy currency, onto the amino acid tyrosine in a target protein; many of the internal ones also carry a domain of about 100 amino acids, later named SH2 (src homology 2), that reads those tags 4,7. Their genes are scattered across the genome, from ABL1 on chromosome 9 and RET on chromosome 10 to BTK (Bruton's tyrosine kinase) on the X chromosome 11,14,17. For scale, the SRC protein, named for the Rous sarcoma virus that carries an altered copy of its gene, is about 60 kilodaltons, the insulin receptor's precursor is 1,370 amino acids long, and the leukemic fusion protein BCR-ABL is about 210 kilodaltons 9,10,11.

Why it matters

They are how many growth signals, insulin's among them, cross the cell membrane and get passed on inside 4,25. Jammed on, single members drive chronic myeloid leukemia, a subset of lung cancers and gastrointestinal stromal tumors, which arise in the wall of the gut, and since imatinib and its successors arrived, people diagnosed with that leukemia in Sweden have come to lose, on average, fewer than three years of life to it, a gain the registry's authors credit to the drugs together with transplantation and other care 11,26,27,28. By 2026, 74 of the 94 kinase inhibitors approved in the United States were aimed at tyrosine kinases, now used in arthritis, eczema and hives as well as cancer 21,22. And the idea of a "natural tyrosine kinase inhibitor" in food traces to test-tube work on soy genistein 29, while no trial among this page's sources shows any food or supplement acting as one in people 30,31.

When it is lost

Losing one tyrosine kinase can be a disease of its own. Boys with a broken BTK gene make almost no B cells or antibodies (X-linked agammaglobulinemia) 8,17; children with two broken copies of JAK3 (Janus kinase 3) have severe combined immunodeficiency, an inherited failure of most immune defenses from infancy 32; a broken TRKA, the receptor for nerve growth factor, abolishes pain and sweating 33; and defects in insulin signaling, the insulin receptor included, cause some of the most severe insulin resistance known 34.

When it is stuck on

A kinase that cannot switch off drives growth no signal asked for: BCR-ABL in chronic myeloid leukemia 11, JAK2 V617F in polycythemia vera, a marrow cancer that overproduces red cells 13,35, KIT in gastrointestinal stromal tumors 27, the mutant EGF receptor (EGFR) and fused ALK (anaplastic lymphoma kinase) in lung cancer 16,26,36, inherited RET mutations in a familial thyroid cancer syndrome 14,37, and FGFR3 (fibroblast growth factor receptor 3) in achondroplasia, where the result is not cancer but short bones 15,38.

Some of the drugs' side effects are on-target, the intended block applied to a healthy tissue that needs the kinase: the acne-like rash of EGFR inhibitors comes from blocking a receptor the skin depends on 39, and heart damage on imatinib has been argued to come from blocking ABL in heart muscle 40.

What a tyrosine kinase is

A kinase is an enzyme that takes the outermost phosphate group from ATP, adenosine triphosphate, the molecule cells use to carry energy, and attaches it to something else 4. Protein kinases attach it to proteins, mostly on one of three amino acids that carry a suitable chemical handle: serine, threonine or tyrosine; several others, histidine among them, can be phosphorylated too but are far less understood 41. Tyrosine kinases are the ones that choose tyrosine. All the cloned tyrosine kinases share a related catalytic domain with a series of conserved motifs, most of which they also share with the serine and threonine kinases 4.

This page is about a family, not a single protein. A 2000 search of the human genome found 90 tyrosine kinase genes and five pseudogenes, broken copies that make no working enzyme; 58 of the 90 are receptors, in 20 subfamilies, and 32 are non-receptor kinases, in 10 3. The full catalog of human protein kinases published two years later counted 518 genes in all, and found that 244 of them map to places in the genome linked with disease or amplified in cancer 6. Hunter, writing in 2009, put the human total at 525, with the same 90 tyrosine kinases among them; the exact count drifts as genome annotation improves 4. Four of the 58 receptors, among them ERBB3, a relative of the EGF receptor, were predicted from their sequences to lack catalytic activity 4,5. For ERBB3 the prediction was overturned in 2010: its purified kinase domain bound ATP and phosphorylated itself, though far less actively than the EGF receptor, and it did not phosphorylate other peptides 5. That was test-tube and crystal-structure work; its authors argued that the weak activity may matter for signaling within receptor pairs, which such work cannot show directly 5.

The two branches are built differently. A receptor tyrosine kinase has a binding domain outside the cell, a single stretch that crosses the membrane, and the kinase inside 4. A non-receptor tyrosine kinase has no membrane-crossing stretch; most float in the cell's interior, and a few are held to membranes by a fatty anchor, the myristoyl group 4. Many of the non-receptor kinases share a catalytic domain of about 260 amino acids and, just ahead of it, a domain of about 100 amino acids that the receptors lack; Tony Pawson's group showed in 1986 that this second domain shapes what the kinase does in a cell without being needed for its chemistry 7. It became known as SH2, src homology 2, and the kinase domain itself as SH1; BTK, for example, carries SH1, SH2 and SH3 domains, SH3 being a module that binds short proline-rich stretches of other proteins 4,8.

The mark tyrosine kinases leave is rare. Phosphotyrosine accounts for less than 1% of the phosphate attached to the proteins of a cell; the rest sits on serine and threonine 4. Hunter gives three reasons: phosphotyrosine rarely has a structural role, most tyrosine kinases are kept switched off unless something specific turns them on, and the enzymes that remove the phosphate, of which 108 can act on phosphotyrosine in the human genome, work very fast 4. A normal tyrosine signal is brief: phosphotyrosine has a very short half-life unless a binding partner shields it 4. That is part of why a kinase that never switches off is so damaging.

In three sentences each

A phosphate on tyrosine is a docking signal

The main job of a phosphorylated tyrosine is not to change the protein that carries it but to be recognized: SH2 domains and PTB (phosphotyrosine-binding) domains on other proteins bind it, and the amino acids just after the tyrosine decide which ones 1,2,4. Signals are passed along by assembling the right partners in the right place.

Receptors switch on in pairs

A receptor tyrosine kinase spans the membrane once. A growth factor binds the outside, receptors come together, and each kinase phosphorylates its partner on tyrosines in the activation loop or near the membrane; those tyrosines then recruit SH2 proteins that start the RAS-ERK pathway, a relay through the small switch protein RAS to a chain of kinases ending in ERK (extracellular signal-regulated kinase), and the pathway of PI3 kinase (phosphoinositide 3-kinase), an enzyme that phosphorylates a fat in the cell membrane 4,42.

Non-receptor kinases work from inside

SRC, ABL, the JAKs (Janus kinases) and BTK have no transmembrane segment 4. Some ride on membranes by a lipid anchor; others serve as the missing kinase for receptors that have none of their own, as JAK3 does for a family of cytokine receptors 4,8,32.

Drugs fit a shape or a pocket

Imatinib binds ABL only in its switched-off shape, which is why it can be selective 43; asciminib binds a different site altogether, the myristoyl pocket away from where ATP sits, and holds the enzyme in an inactive shape 44,45; ibrutinib bonds permanently to one cysteine in BTK 46.

Resistance changes the lock

Cancers escape by mutating the drug's binding site, most famously the threonine-to-isoleucine change T315I in BCR-ABL, by making more copies of the kinase, or by switching to another pathway 4,46,47.

The words, defined

Kinase
An enzyme that attaches a phosphate group, taken from ATP, to another molecule.
ATP
Adenosine triphosphate, the small molecule cells use to carry chemical energy; kinases take its third phosphate.
Phosphorylation
The attachment of a phosphate group. On a protein it changes the protein's charge and shape, or makes it recognizable to other proteins.
Tyrosine
One of the twenty amino acids in proteins, with a ring-shaped side chain ending in a hydroxyl group that can take a phosphate.
Receptor tyrosine kinase
A tyrosine kinase built into the cell's outer membrane, with a binding site outside for a growth factor or hormone and the kinase inside.
Non-receptor tyrosine kinase
A tyrosine kinase that works inside the cell without crossing the membrane, such as SRC, ABL, JAK or BTK.
Domain
A section of a protein that folds on its own and does one job, such as binding or catalysis.
SH2 domain
A protein module of about 100 amino acids that binds a phosphorylated tyrosine; it is how tyrosine signals are read.
Pseudogene
A broken copy of a gene that no longer makes a working protein.
Kinome
The complete set of protein kinase genes in a genome.
SH3 domain
A protein module that binds short stretches rich in the amino acid proline on other proteins; many non-receptor tyrosine kinases carry one beside their SH2 domain.

The whole history, including the reversals

The story runs through three lines of work that began apart. Two of them, tumor viruses that turned out to carry stolen cellular genes and growth factors that turned out to act through receptor kinases, met in the late 1970s and early 1980s 48; the third, a leukemia chromosome, joined them when its fusion product proved to be a tyrosine kinase 11. The reversals are marked; each was made by people working carefully with the evidence of their day.

The history31 dated steps, c. 1960 to 2026. 8 of them overturned something the field had believed.
  1. c. 1960Seen

    A small chromosome in Philadelphia

    Peter Nowell and David Hungerford notice an abnormally small chromosome in the cells of patients with chronic myeloid leukemia; by 1962 it is being called Ph1, the Philadelphia chromosome 49,50.
  2. 1962Seen

    A protein that opens eyes early

    Stanley Cohen isolates a protein from mouse salivary glands that makes newborn mice open their eyelids and cut their incisors early. It becomes epidermal growth factor, EGF 51.
  3. 1973Seen

    The chromosome is an exchange

    Janet Rowley, using new fluorescent and Giemsa banding stains, finds a new consistent chromosomal abnormality in chronic myeloid leukemia; the Philadelphia chromosome is one product of a translocation, an exchange of pieces between chromosomes 9 and 22 11,49,52.
  4. 1976Explained

    The virus stole the gene

    Dominique Stehelin, Harold Varmus, J. Michael Bishop and Peter Vogt show that DNA related to the cancer gene of Rous sarcoma virus is present in normal bird DNA. Cancer genes can be normal cellular genes gone wrong 53; Bishop and Varmus share the 1989 Nobel Prize in Physiology or Medicine for it 54,55,56.
  5. 1978Overturned

    Threonine, it was thought

    Prompted by Ray Erikson's report that the kinase activity of the src protein is specific for threonine, Tony Hunter's laboratory sets out to look for a similar activity in polyomavirus middle T 57.
  6. 1979Seen

    Tyrosine, it was

    In the summer of 1979 a fortuitous observation shows that the kinase activity bound to polyomavirus middle T phosphorylates tyrosine, a modification nobody had seen 4,18.
  7. 1980Explained

    src is a tyrosine kinase, and so is the EGF receptor

    Hunter and Bartholomew Sefton show that src phosphorylates tyrosine and that transformed chicken cells carry up to eight times more phosphotyrosine 9. The same year Hisao Ushiro and Cohen find that the kinase switched on by EGF also phosphorylates tyrosine 58.
  8. 1982Explained

    Insulin's receptor too

    Masato Kasuga and C. Ronald Kahn show that insulin makes its receptor phosphorylate itself on tyrosine 25.
  9. 1984Explained

    A bird virus carries a growth factor receptor

    Peptides of the human EGF receptor turn out to match the v-erbB cancer protein of avian erythroblastosis virus at 74 of 83 amino acids; the virus appears to carry the receptor minus the part that binds EGF 59. In the same year the breakpoints of the Philadelphia chromosome are found clustered in one small region of chromosome 22, named bcr 12.
  10. 1986Explained

    SH2

    Pawson's group describes a conserved noncatalytic domain in cytoplasmic tyrosine kinases; it becomes SH2, the module that reads phosphotyrosine 2,7.
  11. 1990Explained

    BCR-ABL causes the leukemia

    George Daley, Richard Van Etten and David Baltimore give mice the BCR-ABL gene and produce a disease closely resembling chronic myeloid leukemia 11.
  12. 1993Seen

    A missing kinase, a missing immune system

    Two groups find that the gene behind X-linked agammaglobulinemia encodes a tyrosine kinase, later named BTK 8,17.
  13. 1996Trial

    A compound that spares normal colonies in a dish

    Brian Druker and Ciba-Geigy scientists show in laboratory colony assays that the compound later called imatinib cuts leukemic colonies from patients' marrow by 92 to 98% without inhibiting normal ones 60.
  14. 1998Explained

    KIT in stromal tumors

    Gain-of-function KIT mutations are found in gastrointestinal stromal tumors 27.
  15. 2001Approved

    Imatinib

    After a phase 1 trial in which 53 of 54 patients on adequate doses had complete blood responses, imatinib is approved for chronic myeloid leukemia on 10 May 2001 4,61.
  16. 2001Overturned

    Resistance arrives

    Weeks after approval, relapsing patients are reported to carry a single amino acid change in the drug's binding site, or extra copies of BCR-ABL 47.
  17. 2003Approved

    Gefitinib for everyone

    Gefitinib receives US accelerated approval for lung cancer after chemotherapy, in patients not selected by tumor genetics, on a response rate of 10.6% 62.
  18. 2004Seen

    Who responds to gefitinib

    EGFR mutations are found in lung cancers that respond dramatically to gefitinib, and are commoner in tumors from Japan than from the United States 26,63.
  19. 2005Seen

    JAK2 V617F

    One mutation in JAK2 is found in most patients with polycythemia vera 13,35.
  20. 2009Overturned

    Worse without the mutation

    IPASS shows gefitinib beats chemotherapy in EGFR-mutant lung cancer and is worse than chemotherapy without the mutation 64.
  21. 2010Overturned

    Stopping imatinib

    The STIM trial stops imatinib in 100 patients in deep remission; about four in ten stay in remission at a year 65.
  22. 2013Overturned

    Ponatinib and the arteries

    Arterial blockages on ponatinib prompt dose reductions from October 2013; five-year cumulative arterial events reach 31% in chronic phase 66,67. Sales are suspended at the FDA's request, then reauthorized 68,69.
  23. 2014Overturned

    The permanent bond breaks

    Resistance to ibrutinib, a drug that bonds irreversibly to BTK, is traced to a change of the bonded cysteine to serine 46.
  24. 2015Overturned

    Gefitinib for the mutation only

    After a survival trial failed overall 70, gefitinib is approved again in the United States, only for tumors carrying EGFR exon 19 deletions or the L858R mutation 71.
  25. 2018Trial

    EURO-SKI

    758 patients stop treatment; half remain free of molecular relapse at two years 23.
  26. 2021Policy

    The JAK boxed warning widened

    On 9 September 2021 the US Food and Drug Administration requires the boxed warnings of three JAK inhibitors to be revised to include heart events, cancer, blood clots and death, based on one tofacitinib safety trial 72.
  27. 2021Approved

    A drug that binds elsewhere

    On 29 October 2021 asciminib, which binds the myristoyl pocket instead of the ATP site, is approved in the United States for chronic myeloid leukemia after two or more earlier inhibitors, and for disease carrying T315I 73.
  28. 2022Overturned

    ORAL Surveillance published

    Tofacitinib fails to prove itself as safe as tumor necrosis factor (TNF) inhibitors in 4,362 older patients with rheumatoid arthritis and a cardiovascular risk factor 22.
  29. 2024Trial

    Asciminib first

    ASC4FIRST: the allosteric drug asciminib gives more major molecular responses than standard first treatment in newly diagnosed chronic myeloid leukemia 45.
  30. 2025Approved

    Ten more

    Ten kinase inhibitors are approved in the United States in one year, among them BTK inhibitors for hives and immune thrombocytopenia and a JAK inhibitor for hand eczema 21.
  31. 2026Trial

    Fixed-duration non-covalent BTK inhibition

    BRUIN CLL-322 adds a fixed course of pirtobrutinib to venetoclax and rituximab in relapsed chronic lymphocytic leukemia and improves progression-free survival 74.

How tyrosine phosphorylation was found

The gene at the start of this story, src, is named for Rous sarcoma virus, a chicken tumor virus whose cancer-causing protein it makes 9. The turn came in 1976, when Stehelin, Varmus, Bishop and Vogt showed that DNA related to the virus's transforming gene, src, was present in the DNA of normal birds 53. The virus had not invented its cancer gene. It had picked up a normal cellular gene and carried it in an altered form, an idea for which Bishop and Varmus shared the 1989 Nobel Prize in Physiology or Medicine 54,55,56.

The next question was what the src protein did. Ray Erikson's group had reported that it carried a kinase activity specific for threonine, and in 1978, prompted by that, Tony Hunter's laboratory at the Salk Institute set out to see whether the transforming protein of a second virus, polyomavirus middle T, behaved the same way 57. It did have a kinase activity attached, but the phosphorylated amino acid behaved, in acid, in alkali and on one- and two-dimensional separations, exactly like phosphotyrosine and unlike phosphoserine, phosphothreonine, phospholysine or phosphohistidine 18. Hunter has described the finding as serendipitous and the observation about src that followed as fortuitous 4,57. Hunter and Walter Eckhart later titled their own account of the discovery "The discovery of tyrosine phosphorylation: it's all in the buffer!" 75. Electrophoresis is the separation of charged molecules in an electric field, and the buffer is the salt solution in which it runs; the title makes that buffer the hinge of the story 75. The detail usually retold, that the buffer was old and had drifted in pH and so pulled phosphotyrosine apart from phosphothreonine, is attributed to that account, whose text was not opened for this page, so it is given here as the discoverers' recollection rather than a checked detail 75.

The src result came quickly. Hunter and Sefton found that pp60src phosphorylated tyrosine in a test tube, that chicken cells transformed by Rous sarcoma virus contained as much as 8-fold more phosphotyrosine than uninfected cells, and that the normal cellular version of src, present in all vertebrate cells, phosphorylated tyrosine as well 9. Hunter later wrote that every experiment in that March 1980 paper was done in less than a month 57. Erikson's threonine was the field's first reversal, and it was overturned by a laboratory that had set out to find the same activity in a different virus 57.

Growth factors joined the story the same year. Stanley Cohen had isolated, in 1962, a mouse salivary-gland protein that made newborn mice open their eyes and cut their teeth early, the protein that became epidermal growth factor 51. In 1980 Hisao Ushiro and Cohen showed that the kinase EGF switched on in membranes of a human carcinoma cell line, A-431, phosphorylated tyrosine, and that the purified receptor complex did so itself 58. In 1982 insulin was shown to make its own receptor phosphorylate itself on tyrosine 25, and in 1985 the sequence of the 1,370-amino-acid insulin receptor precursor showed its kinship with both the EGF receptor and the src family 10. The 1984 finding that the v-erbB cancer protein of a bird virus closely matches the EGF receptor, and appears to be a version of it missing its EGF-binding part, tied the two lines together 48,59; its authors proposed that the virus may cause cancer partly by carrying such a truncated receptor 59.

The last piece was how a phosphate on tyrosine passes a message on. Pawson's group described in 1986 a domain of about 100 amino acids, conserved in the cytoplasmic tyrosine kinases, that changed what the kinase did in cells without being needed for its catalysis 7. Over the following years it emerged that this domain, SH2, binds phosphotyrosine, and that the amino acids immediately after the tyrosine decide which SH2 protein binds 2,4. Hunter's argument for why evolution chose tyrosine at all rests here: an SH2 domain can make contacts with the tyrosine's ring as well as its phosphate, so it binds phosphotyrosine more strongly than it could bind phosphoserine or phosphothreonine 4.

  • BCR-ABL1 transcript level by quantitative polymerase chain reaction (PCR)Counts the messenger RNA of the leukemic fusion gene in blood by a method that copies a chosen stretch of genetic material until it can be measured, reported on an International Scale; a major molecular response is a level of 0.1% or less of the standardized baseline 45.To follow patients with chronic myeloid leukemia on treatment, and to decide who may try stoppingSensitive enough that the first stopping trial required a fall of more than five logs (to below one hundred-thousandth of the starting level), with transcripts undetectable, for at least two years 65.A deep response is not a cure: about half of patients in deep molecular remission lost their major molecular response within two years of stopping 23.
  • Tumor genotyping for EGFR, ALK, ROS1 and RETSequencing or rearrangement testing of tumor tissue to find a kinase driver before the first treatment 26,36.In advanced lung adenocarcinoma, cancer of the lung's gland-forming cells, before choosing first treatmentThe result decides which way the drug works: in IPASS, gefitinib lowered the risk of progression in EGFR-mutant tumors (hazard ratio 0.48, about half the risk) and raised it in tumors without the mutation (hazard ratio 2.85, nearly three times the risk) 64.Each fusion is rare and has to be looked for specifically; about 1,500 tumors were screened to find 82 eligible ALK-positive patients for the first crizotinib study 36.
  • Kinase-domain mutation testingSequencing of the drug-binding part of the kinase when a response is lost 47.When chronic myeloid leukemia or chronic lymphocytic leukemia stops respondingFound the T315I-type change in 6 of 9 relapsing patients in the first series 47, and BTK C481S in 5 of 6 on ibrutinib 46.Not every escape is a kinase mutation: extra copies of BCR-ABL, or mutations in PLCG2 (phospholipase C gamma 2), the next enzyme in the chain, were the cause in others 46,47.
  • JAK2 V617F testA blood test for the single mutation that switches JAK2 on 13.In suspected polycythemia vera, essential thrombocythemia and myelofibrosisDetection depends on the method: one 2005 series of 244 patients found it in 65% of polycythemia vera, 57% of myelofibrosis and 23% of essential thrombocythemia 13, while a more sensitive test that amplifies only the mutant gene found it in 97% of 73 patients with polycythemia vera, 57% of 51 with essential thrombocythemia and 50% of 16 with myelofibrosis 111.A negative result does not exclude these diseases: the mutation is absent in roughly half of essential thrombocythemia and myelofibrosis 111, and some patients with V617F-negative polycythemia vera carry other activating JAK2 mutations, in exon 12 148.
  • Heart, blood pressure and electrocardiogram (ECG) monitoring on treatmentThe QT interval, the heart's electrical recovery time, on the electrocardiogram (ECG), heart pumping function on echocardiography and blood pressure, as set out in cardio-oncology guidance 126.Before and during many tyrosine kinase inhibitorsOn sunitinib, 28% of patients at the approved dose lost at least 10 points of ejection fraction, the share of blood the heart pumps out with each beat, and 47% of all 75 treated developed hypertension 124.Rare harms escape routine checks: dasatinib-associated pulmonary arterial hypertension, estimated at no less than 0.45% of exposed patients, needs a specific search 129.

How the signal passes: receptors, pairs and docking sites

For a receptor tyrosine kinase the sequence is the same in outline across the family. A ligand, such as a growth factor or a cytokine, binds the outside of the receptor 4. The receptors come together in pairs or larger groups, and each receptor's kinase phosphorylates its neighbor on tyrosines in the activation loop, a flap that controls access to the catalytic site, or just inside the membrane 4. The newly phosphorylated tyrosines recruit proteins with SH2 domains or PTB (phosphotyrosine-binding) domains, a second kind of module that reads the mark, and those start the signaling chains that reach the nucleus, chief among them the RAS-ERK pathway, a relay of the small switch proteins RAS and a chain of kinases ending in ERK (extracellular signal-regulated kinase), and the PI3 kinase pathway, named for phosphoinositide 3-kinase, an enzyme that phosphorylates a fat in the cell membrane 4. The details of how the ligand brings the receptors together turned out to be surprisingly diverse from one receptor to the next 42.

Phosphorylation does change some proteins directly, by adding charge or altering their shape, but Hunter argues that its most important job is to create a docking site 1. Pawson's summary is that modular binding between short phosphorylated motifs and domains like SH2 is the framework on which signaling pathways are assembled and controlled, and that systems this simple at the level of a single contact can still produce complicated cellular behavior 2. A tyrosine kinase is less a switch than a way of briefly assembling a particular team of proteins at a particular spot on the membrane 4.

Non-receptor kinases reach the same end from inside. Some are activated when a receptor without its own kinase clusters after binding its ligand, and act as that receptor's catalytic part 4; JAK3, for example, works with the cytokine receptors that share a component called the common gamma chain, and children who lack JAK3 have the same pattern of severe combined immunodeficiency as children who lack the gamma chain itself 32. BTK sits in the signaling chain from the B-cell receptor, the antibody-like receptor on B cells, and is essential to B-cell development and survival 8,76.

The pathways downstream are shared with other entries in the Atlas. The RAS-ERK chain is the one in which RAS proteins, among them KRAS, which has its own Atlas entry, relay the signal from the receptors toward the nucleus 4. Hunter's 2009 review already noted emerging evidence that inhibiting one tyrosine kinase can lead a tumor to switch on a second receptor that does the same job, and suggested that combinations of inhibitors might therefore work better 4.

The words, defined

Ligand
The molecule that binds a receptor and switches it on, such as EGF for its receptor or insulin for the insulin receptor.
Dimerization
Two receptor molecules coming together; for most receptor tyrosine kinases it is the step that switches the kinase on.
Autophosphorylation
A kinase phosphorylating itself or, in a receptor pair, its partner.
Activation loop
A flexible flap in the kinase domain whose position, often set by its own phosphorylation, opens or closes the enzyme's active site.
Docking site
A phosphorylated tyrosine, with the amino acids around it, that a particular SH2 or PTB domain recognizes and binds.
Cytokine
A small signaling protein, mostly of the immune system; many cytokine receptors have no kinase of their own and borrow a JAK.

The family, member by member: lost, and stuck on

The diseases these kinases cause can be sorted by direction. In the examples on this page, a lost kinase means a silent signal and, usually, an inherited defect present from birth; a kinase stuck on means a signal that never stops and, most often, a cancer. The table gathers the members that matter most in medicine, with the evidence for each.

The losses are mostly rare inherited diseases. The gene for X-linked agammaglobulinemia, a disease in which boys make almost no mature B cells or antibodies, was identified in 1993 as a src-related tyrosine kinase, BTK (Bruton's tyrosine kinase), which its discoverers called the first evidence that mutations in a src-related gene cause human genetic disease 8,17. It was not the first tyrosine kinase behind an inherited disease: mutations in the insulin receptor had been found in 1988 in two patients with extreme insulin resistance, one of them with leprechaunism, a severe inherited form 77,78, and a mutation in the kinase domain of KIT, the receptor for mast cell and stem cell growth factor, in 1991 in a family with piebaldism, an inherited patchy absence of pigment in skin and hair 79. Two children with an autosomal form of severe combined immunodeficiency carried homozygous mutations in JAK3 32. Three unrelated patients who felt no pain and could not sweat carried mutations in the kinase domain of TRKA, the receptor for nerve growth factor 33. And rare monogenic defects in insulin signaling, including the insulin receptor, cause an unusually severe insulin resistance that is biochemically distinct from the common kind that comes with obesity 34.

The gains are mostly acquired in a single tissue, and they are where the drugs came from. BCR-ABL, made by the Philadelphia chromosome, is enough to cause a chronic myeloid leukemia-like disease in mice 11. One mutation, V617F, in the pseudo-kinase domain of JAK2, a domain that looks like a kinase but has no catalytic job of its own, switches the neighboring real kinase on and is found in most patients with polycythemia vera 13,35. KIT mutations make the receptor active without its ligand in gastrointestinal stromal tumors, and a different KIT mutation, D816V, is the main driver of indolent systemic mastocytosis, a clonal disease of mast cells in which anaphylaxis occurs in up to half of patients 27,80. Inherited gains exist too. A mutation of RET, a receptor tyrosine kinase gene, at the same conserved cysteine was found in 19 of 20 families with multiple endocrine neoplasia type 2A who carried RET mutations, an inherited syndrome of medullary thyroid cancer and adrenal tumors 14, and such germline mutations turn RET into a constantly active, transforming kinase in cultured cells 37. In achondroplasia the same change in FGFR3 (fibroblast growth factor receptor 3), glycine to arginine at position 380, was found on all 16 affected chromosomes studied, 15 by one DNA change and one by another at the same position 15; in cultured cells it activates the receptor without its ligand 38, a gain that stunts bone growth rather than causing cancer. That gain has now been treated with a tyrosine kinase inhibitor: in PROPEL 3, 114 children aged 3 to 17 with achondroplasia were randomized two to one to oral infigratinib, which blocks FGFR1 to FGFR3, or placebo for 52 weeks; growth in height was 1.74 cm a year faster on the drug, the ratio of upper to lower body length did not differ significantly, and the trial was funded by BridgeBio Pharma, which develops the drug 81.

KinaseTypeWhen lostWhen stuck onDrugs that block it
ABL1Non-receptorNot covered hereFused to BCR as BCR-ABL: chronic myeloid leukemia 11Imatinib, dasatinib, nilotinib, ponatinib, asciminib 4,44,82
SRCNon-receptorNot covered hereViral v-src transforms chicken cells 9Dasatinib, a mixed SRC and ABL inhibitor 4
JAK2Non-receptorNot covered hereV617F: polycythemia vera, myelofibrosis, essential thrombocythemia 13Ruxolitinib 83
JAK3Non-receptorSevere combined immunodeficiency 32Not covered hereJAK inhibitors such as tofacitinib, used in arthritis 22
BTKNon-receptorX-linked agammaglobulinemia 8,17Chronic lymphocytic leukemia cells depend on its signaling 76Ibrutinib, zanubrutinib, pirtobrutinib 76,84,85
EGFRReceptorNot covered hereMutated in a subset of lung adenocarcinomas 26,63Gefitinib, erlotinib, osimertinib 64,86
HER2 (ERBB2)ReceptorNot covered hereOverexpressed in a subset of breast cancers 4Lapatinib; trastuzumab is an antibody 4,87
ALK (anaplastic lymphoma kinase)ReceptorNot covered hereA fusion of ALK with a gene called EML4 in 5 of 75 (6.7%) lung cancers in the first series 16Crizotinib and successors 36
ROS1ReceptorNot covered hereGene fusions in lung cancer 88Crizotinib, taletrectinib 21,88
RETReceptorNot covered hereInherited mutations in multiple endocrine neoplasia type 2A (MEN 2A); fusions in 1-2% of lung cancers 14,37,89Selpercatinib 89
KITReceptorPiebaldism 79Gastrointestinal stromal tumor; D816V in systemic mastocytosis 27,80Imatinib, avapritinib 80,90
FLT3 (FMS-like tyrosine kinase 3)ReceptorNot covered hereMutated in a subset of acute myeloid leukemia 91Midostaurin, gilteritinib 91,92
VEGF (vascular endothelial growth factor) and PDGF (platelet-derived growth factor) receptorsReceptorNot covered hereTargeted for their role in tumor blood vessels 4,93Sunitinib, sorafenib 93,94
FGFR3ReceptorNot covered hereG380R: achondroplasia 15,38Infigratinib, in a 2026 phase 3 trial in achondroplasia 81
TRKA (NTRK1)ReceptorCongenital insensitivity to pain with anhidrosis 33Not covered hereLarotrectinib, for cancers with TRK fusions 95
Insulin receptorReceptorSevere genetic insulin resistance, among the primary signaling defects 34,77,78Not covered hereNone

The words, defined

Severe combined immunodeficiency
An inherited failure of the immune system, present from infancy, in which T cells and with them most defenses are missing.
Autosomal, homozygous
Autosomal means carried on a chromosome other than the sex chromosomes; homozygous means both copies of the gene carry the change.
Anaphylaxis
A sudden, severe, whole-body allergic reaction.
Germline mutation
A change present in the egg or sperm, and so in every cell of the body, that can be passed to children.

The Philadelphia chromosome and BCR-ABL

The story of chronic myeloid leukemia begins with a chromosome. Around 1960, in Philadelphia, Peter Nowell and David Hungerford noticed an abnormally small chromosome in the cells of patients with what was then called chronic granulocytic leukemia; Nowell, looking back in 2007, dated it to almost 50 years earlier 49. By 1962 it was being written Ph1, for Philadelphia 50.

In 1973 Janet Rowley applied two new staining methods, quinacrine fluorescence and Giemsa banding, which give each chromosome a barcode of light and dark bands, and found a new consistent abnormality in the disease 52. The small chromosome turned out to be one product of a translocation, an exchange of pieces between chromosomes 9 and 22, which leaves chromosome 22 shortened and joins part of the BCR gene on 22 to the ABL1 gene from 9 11,12,49. ABL1 is named for the Abelson mouse leukemia virus, which carries an altered copy of it 11. In 1984 Groffen and colleagues showed that the breaks on chromosome 22 fell, in 17 of 19 patients, within a stretch of DNA no longer than 5.8 kilobases, which they named the breakpoint cluster region, bcr; the two patients without such a break did not have the Philadelphia chromosome either 12.

The fusion makes a hybrid protein, P210 BCR-ABL, named for its size of about 210 kilodaltons, whose structure and tyrosine kinase activity resemble those of the cancer protein of Abelson murine leukemia virus, and whose kinase is permanently on 11,61. Whether that protein caused the leukemia or merely marked it was settled in 1990, when George Daley, Richard Van Etten and David Baltimore put it into mouse bone marrow and transplanted the marrow: the recipients developed a myeloproliferative disease closely resembling the chronic phase of the human disease 11. The evidence was in mice, but it pointed at one enzyme as the cause of one human cancer, which is what made it worth trying to block.

The chromosome is still how the disease is diagnosed and followed. Karyotyping, the microscopic examination of chromosomes in dividing cells, measured response in the first imatinib trials: a major cytogenetic response meant that no more than 35% of cells in metaphase, the stage of division when chromosomes can be seen, still carried the Philadelphia chromosome 61. Polymerase chain reaction tests for BCR-ABL messenger RNA now provide the finer measure, and decide who may try stopping treatment 23,65.

The words, defined

Translocation
An exchange of segments between two chromosomes; in chronic myeloid leukemia it joins part of BCR on chromosome 22 to ABL1 from chromosome 9.
Karyotype
The set of chromosomes in a cell as seen under the microscope, arranged by size and banding pattern.

Imatinib: the pill that proved the point

Imatinib did not start as a leukemia drug. At Ciba-Geigy, a program to make inhibitors of protein kinase C, a serine and threonine kinase, produced a chemical scaffold called 2-phenylaminopyrimidine; one target pursued with it was the receptor for platelet-derived growth factor, PDGF, in the hope of preventing the re-narrowing of arteries after angioplasty, the widening of a narrowed artery with a balloon 4. The derivative CGP57148B inhibited the PDGF receptor and v-ABL equally potently, and KIT as well; it was renamed STI571, for signal transduction inhibitor, and became imatinib 4,19. Its activity against KIT later gave it a second disease, gastrointestinal stromal tumors 4.

The laboratory case came in 1996. Brian Druker at Oregon, working with the company's scientists, showed that the compound blocked the growth of cells carrying BCR-ABL and, in colony assays, in which single cells from blood or marrow are grown in a dish to see how many form colonies, using samples from patients with chronic myeloid leukemia, cut the number of BCR-ABL colonies by 92 to 98% without inhibiting normal colony formation 19,60. In 2000 the crystal structure, an atom-by-atom map of the drug bound to the enzyme, showed why it could be so choosy: imatinib binds ABL only when the kinase is in an inactive shape, with its activation loop unphosphorylated, a shape distinct from that of closely related kinases such as SRC 43. All kinases bind ATP, but they switch themselves off in different ways, and a drug that recognizes the off state can tell them apart 43.

The clinical result arrived fast. In the phase 1 trial, 83 patients with chronic-phase disease in whom interferon, an immune protein that was the standard drug before imatinib, had failed received doses from 25 to 1,000 mg a day; no maximum tolerated dose was found, and 53 of the 54 who received 300 mg or more had a complete hematologic response, meaning normal blood counts, usually within four weeks 61. A companion trial in the same issue treated 58 patients whose disease had reached blast crisis, the aggressive late phase, or who had Philadelphia-positive acute lymphoblastic leukemia: 55% of 38 with myeloid blast crisis and 70% of 20 with lymphoid disease responded, but all but one of the lymphoid patients relapsed 96. Imatinib went into trials in 1998 and was approved for chronic myeloid leukemia on 10 May 2001 4. The same issue of the New England Journal of Medicine carried a report of the drug in one patient with a metastatic gastrointestinal stromal tumor 97.

IRIS, the randomized trial against the previous standard, enrolled 1,106 newly diagnosed patients 98. At 18 months the rate of major cytogenetic response was 87.1% with imatinib against 34.7% with interferon and low-dose cytarabine, and complete cytogenetic response, no Philadelphia-positive cells at all, 76.2% against 14.5% 98. At a median follow-up of 10.9 years the estimated overall survival in the imatinib arm was 83.3%, and serious adverse events judged related to the drug were uncommon and mostly in the first year 20. The comparison arm cannot speak to survival, because 65.6% of its patients crossed over to imatinib after a median 0.8 years 20. The long-term report was funded by Novartis, the drug's maker 20.

The population figures say the same thing more plainly. In Sweden's cancer registry, which captured 2,662 patients diagnosed between 1973 and 2013, life expectancy rose steeply over the period, and patients diagnosed in 2013 were predicted to lose, on average, fewer than three years of life to the disease 28. The authors credit imatinib and later tyrosine kinase inhibitors together with transplantation and other improvements, which is the correct caution for registry data 28.

Resistance, and the drugs built to get around it

Resistance appeared almost at once, in patients with advanced disease who had responded and then relapsed. In 2001 Mercedes Gorre, Charles Sawyers and colleagues found that resistance came with BCR-ABL signaling switched back on in every case examined; in six of nine patients a single change of threonine to isoleucine in the drug's binding site, the mutation now called T315I, was responsible, and in three the gene had been copied many times over 47. The cancer had kept its dependence on the one kinase and changed the lock 47. Threonine 315 is the gatekeeper residue of the kinase; isoleucine's bulkier side chain physically blocks imatinib from the cleft 4. The equivalent residue in EGFR, threonine 790, mutates to methionine (T790M) in lung cancers that become resistant to the first EGFR inhibitors 4. It was long thought to work the same way, by crowding the drug out, but in 2008 binding studies showed that T790M mutants still hold gefitinib tightly and instead raise the kinase's affinity for ATP more than tenfold, so that ATP outcompetes the drug; inhibitors that bond permanently to the enzyme get past it for that reason 99.

Second-generation drugs followed. Dasatinib, which also inhibits SRC, and nilotinib, a more potent and selective relative of imatinib, were developed to inhibit imatinib-resistant forms of BCR-ABL and work for some imatinib-resistant disease 4. Neither overcomes T315I 82. Ponatinib, which inhibits BCR-ABL carrying T315I, did: in the PACE trial of 449 heavily pretreated patients, 70% of those in chronic phase with T315I had a major cytogenetic response 82. The cost showed up in the arteries. Serious arterial thrombotic events were reported in 9% at a median 15 months 82; at five years the cumulative incidence of arterial occlusive events in chronic-phase patients had reached 31%, and dose reductions were brought in from October 2013 to lower the risk 66. In late 2013 marketing of ponatinib in the United States was suspended at the Food and Drug Administration's request 68, and sale was later reauthorized 69; both steps are recorded in news reports whose full texts were not opened. The episode became a case study in what accelerated approval can miss 67.

The dose question was then tested properly. OPTIC randomized 283 resistant patients to start ponatinib at 45, 30 or 15 mg a day, with the two higher doses cut to 15 mg once the BCR-ABL level fell to 1% or less 100. The response rate at 12 months was 44.1%, 29.0% and 23.1%, and grade 3 or worse arterial occlusive events occurred in 5, 5 and 3 patients; the best balance came from starting at 45 mg and reducing on response 100. A model built from the trial by the manufacturer's scientists estimated that each 15-mg increase in dose doubled the hazard of an arterial event (hazard ratio 2.05) 101. The hazard ratio is the risk in one group relative to another at any given moment; 2 means twice the risk.

Asciminib went around the problem rather than through it. Every drug before it competed with ATP for the catalytic cleft 44,45. Asciminib binds the myristoyl pocket, a separate site on ABL, and pushes the kinase into an inactive shape; resistance mutations to it and to the catalytic-site drug nilotinib did not overlap, and in mice the combination eradicated transplanted leukemia tumors without recurrence after treatment stopped 44. In ASCEMBL, among 233 patients who had already had two or more tyrosine kinase inhibitors, the major molecular response at 24 weeks was 25.5% with asciminib against 13.2% with bosutinib, and treatment was stopped for side effects in 5.8% against 21.1% 102. On 29 October 2021 the US Food and Drug Administration granted asciminib accelerated approval for chronic-phase disease after two or more earlier tyrosine kinase inhibitors, and full approval for disease carrying T315I on the strength of a single-arm study; the first indication was converted to full approval on 12 October 2022, when the major molecular response at 96 weeks in ASCEMBL was 38% against 16% with bosutinib 73.

ASC4FIRST, in 2024, moved it to first treatment. Among 405 newly diagnosed patients, major molecular response at 48 weeks was 67.7% with asciminib and 49.0% with a tyrosine kinase inhibitor chosen by the investigator; within the imatinib stratum the gap was 69.3% against 40.2%, while against second-generation drugs it was 66.0% against 57.8%, a difference whose confidence interval crossed zero and which was not a primary objective 45. Grade 3 or worse adverse events were 38.0% with asciminib, 44.4% with imatinib and 54.9% with second-generation drugs 45. A 2026 systematic review reports the 96-week figures as 74.1% against 52.0%, with hypertension in 10.5% on asciminib and arterial occlusive events at similar low rates in both arms 103. These are response end points, not survival; ASC4FIRST was funded by Novartis, which makes the drug, and ASCEMBL counted Novartis employees among its authors 45,102.

The words, defined

Gatekeeper mutation
A change at the amino acid guarding the back of the ATP pocket, such as T315I in ABL or T790M in EGFR, that makes many inhibitors fail, by crowding the drug out or, for T790M, mainly by making the kinase hold ATP more tightly.
Allosteric inhibitor
A drug that binds a site other than the active site and changes the enzyme's shape; asciminib is one.
Major molecular response
BCR-ABL messenger RNA at 0.1% or less of a standardized baseline on the International Scale.
Cytogenetic response
A fall in the share of dividing marrow cells carrying the Philadelphia chromosome; complete means none are seen.
Hazard ratio
The rate of an event in one group divided by the rate in another; below 1 favors the first group.
Confidence interval
The range within which the true value plausibly lies; if it crosses no difference, the result is not statistically significant.
Accelerated approval
A US route that approves a drug on an early measure, such as tumor response, on condition that later trials confirm a real benefit.
Phase 1, 2 and 3 trials
The stages of drug testing: phase 1 finds a safe dose in a few people, phase 2 looks for an effect, phase 3 compares the drug with standard care in a large randomized trial.
Grade 3 or worse
Side effects severe enough to need hospital care or to disable, on a standard 1-to-5 scale where 5 is death.
Open-label
A trial in which patients and doctors know which treatment each patient receives.
Systematic review, meta-analysis
A review that searches for all studies on a question by a set method; a meta-analysis also combines their numbers.

Stopping treatment: the reversal of 'for life'

Imatinib was given indefinitely, and in 2010 little was known about whether it could ever be stopped safely 65. STIM, in France, tested that directly 65. One hundred patients who had been on imatinib for more than two years, and whose BCR-ABL had been undetectable for at least two years, a fall of more than five logs, meaning to below one hundred-thousandth of the starting level, stopped the drug 65. Of the 69 followed for at least a year, 42 (61%) relapsed, 40 of them within six months; at 12 months the probability of staying in complete molecular remission was 41% 65. Every patient who relapsed responded again when imatinib was restarted 65. The authors raised, carefully, the possibility that some patients might be cured 65.

EURO-SKI confirmed it across Europe. At 61 centers in 11 countries, 758 patients who had taken any tyrosine kinase inhibitor for at least three years and been in deep molecular response for at least a year were enrolled to stop 23. Among the 755 who could be evaluated, molecular relapse-free survival, defined as keeping a major molecular response, was 61% at 6 months and 50% at 24 months 23. Longer treatment and longer deep response predicted success, and stopping was estimated to have saved about 22 million euros 23. In 2026 the Japanese J-SKI study, an observational study whose 795 patients were followed partly prospectively (283) and mostly retrospectively (512), reported a five-year treatment-free remission rate of 65.2% at a median follow-up of 32 months; 99% of those who relapsed regained major molecular response on restarting, each extra year of deep response before stopping lowered the risk of relapse by 12.5%, and a second attempt to stop succeeded in 41% of 32 patients 24.

The reversal has limits that the trials themselves show. These were not randomized trials, and their patients were selected for deep, long responses 23,24,65. Relapse after stopping has been manageable in these studies, in which patients were tested often and restarted promptly; nearly all who relapsed regained their response 24,65. A 2026 case report from Japan describes a man who stopped imatinib in 2018 after years of undetectable disease, lost his deep response in 2022, declined to restart, and within two months of a rising result developed lymphoid blast crisis, the aggressive phase of the disease, needing intensive chemotherapy and a stem cell transplant 104. One case cannot give a rate, but it shows why stopping is a monitored procedure and not a cure to be assumed. The 2025 European LeukemiaNet recommendations, the current international guidance, report that the data on stopping have matured but acknowledge that most patients will remain on treatment for many years, and now favor lowering the dose over switching drugs to manage side effects 105.

The class spreads: lung, breast, blood, gut, kidney and liver

Imatinib's lesson was that a cancer driven by one kinase could be controlled by blocking that kinase. The lesson generalized only as far as the driver did. Gefitinib, an inhibitor of the EGF receptor, received accelerated approval in the United States on 5 May 2003 for lung cancer that had progressed after chemotherapy, on a response rate of 10.6% in 142 patients not selected by tumor genetics, while two trials of 1,093 and 1,037 patients found no benefit from adding it to chemotherapy 62. It produced rapid and often dramatic responses in about 10% of patients with non-small-cell lung cancer and nothing in most of the rest 26; in 2004 two groups found why. Somatic mutations in the kinase domain of EGFR, small deletions or single substitutions clustered around the ATP pocket, were present in 8 of 9 responders and none of 7 non-responders in one series 26, and in 15 of 58 unselected tumors from Japan against 1 of 61 from the United States in the other 63. The first approval had not waited for that answer. In 2005 the ISEL trial, which randomized 1,692 previously treated patients two to one to gefitinib or placebo, found no significant survival gain overall (median 5.6 against 5.1 months, hazard ratio 0.89), with benefit confined to preplanned subgroups such as never-smokers and patients of Asian origin 70. On 13 July 2015 the agency approved gefitinib again, this time only for tumors carrying EGFR exon 19 deletions or the L858R mutation found by an approved test 71.

IPASS made the reversal plain. In 1,217 previously untreated East Asian patients with lung adenocarcinoma who had never smoked or smoked lightly, gefitinib beat carboplatin and paclitaxel overall, but the result split cleanly by the tumor's genes: in 261 patients with EGFR mutations, the hazard ratio for progression or death was 0.48 in gefitinib's favor, and in 176 without, it was 2.85 in chemotherapy's favor 64. The same pill was the better treatment for one group and the worse for the other. Osimertinib, a third-generation drug that also blocks the T790M resistance mutation, then lengthened median progression-free survival against the first-generation drugs from 10.2 to 18.9 months in 556 patients 86, and in 2025 the final FLAURA2 analysis found that adding chemotherapy to osimertinib lengthened median overall survival from 37.6 to 47.5 months (hazard ratio 0.77), at the cost of grade 3 or worse adverse events in 70% against 34% 106. EGFR has its own page in the Atlas.

Fusions, genes joined end to end by chromosome breaks, proved as targetable as point mutations. In 2007 a small inversion on chromosome 2p was found to fuse EML4 to ALK in 5 of 75 lung cancers, and the fusion transformed mouse cells 16. Three years later crizotinib shrank tumors in 57% of 82 ALK-positive patients, found by screening about 1,500 36. The same drug produced responses in 72% of 50 patients with ROS1 fusions 88, and selpercatinib in 64% of 105 previously treated and 85% of 39 untreated patients with RET fusions, which occur in 1 to 2% of these cancers 89. Later drugs went further. In CROWN, 296 untreated patients with ALK-positive lung cancer were randomized to lorlatinib or crizotinib; at seven years 55% on lorlatinib were alive without progression against 3% on crizotinib (hazard ratio 0.19), in a post hoc update with Pfizer-employed coauthors, and overall survival is not yet mature 107. Larotrectinib, an inhibitor of the tropomyosin receptor kinases (TRK), produced responses in 75% of 55 children and adults whose tumors, of 17 different types, carried TRK gene fusions, a result organized by the fusion rather than the organ; it was an uncontrolled pooled analysis funded by the developer, Loxo Oncology, and others 95.

In breast cancer the first drug against a tyrosine kinase was an antibody: trastuzumab, against HER2 (human epidermal growth factor receptor 2, also called ERBB2), approved in 1998 4. Lapatinib, a small-molecule inhibitor of HER2 and EGFR, then lengthened time to progression from 4.4 to 8.4 months when added to capecitabine in women whose disease had progressed after trastuzumab 87. In 2025 HER2 mutations in lung cancer became a target: zongertinib, an irreversible inhibitor selective for HER2, produced confirmed responses in 71% of 75 previously treated patients 108 and 76% of 74 untreated patients 109, in cohorts of a phase 1a-1b trial without a comparison arm funded by its maker, Boehringer Ingelheim; it was among the ten kinase inhibitors approved in the United States in 2025 21. In acute myeloid leukemia, a fast-growing cancer of immature marrow cells, mutations in FLT3 (FMS-like tyrosine kinase 3) mark a poor-prognosis group: RATIFY screened 3,277 adults aged 18 to 59 and randomized 717 to chemotherapy with midostaurin or placebo, with a hazard ratio for death of 0.78 91, and in relapsed disease gilteritinib extended median survival from 5.6 to 9.3 months in 371 patients 92.

Gastrointestinal stromal tumor was imatinib's second disease. KIT mutations had been found in these tumors in 1998 27; in 2002 a randomized trial of two doses in 147 patients with advanced disease, which resists conventional chemotherapy, produced partial responses in 53.7% 90. Other drugs block the receptors for VEGF (vascular endothelial growth factor) and PDGF (platelet-derived growth factor), kinases that tumors depend on to grow blood vessels 4,93. Sunitinib more than doubled progression-free survival in metastatic kidney cancer, 11 against 5 months in 750 patients 94, and sorafenib lengthened median survival in advanced liver cancer from 7.9 to 10.7 months in 602 patients, while shrinking tumors in only 2% and without delaying the time until symptoms worsened, a co-primary outcome (4.1 against 4.9 months) 93. Not every success is a cure, and some are measured in a few months 93.

TargetDiseaseTrial and yearPatientsMain result
BCR-ABLChronic myeloid leukemiaIRIS, 20031,106Major cytogenetic response at 18 months 87.1% vs 34.7% 98
BCR-ABL (myristoyl pocket)Chronic myeloid leukemia, newASC4FIRST, 2024405Major molecular response at 48 weeks 67.7% vs 49.0% 45
EGFRPreviously treated lung cancer, unselectedISEL, 20051,692No significant survival gain, HR 0.89 70
EGFRLung adenocarcinomaIPASS, 20091,217Progression HR 0.48 with mutation, 2.85 without 64
EGFREGFR-mutant lung cancerFLAURA2 survival, 2025557Median survival 47.5 vs 37.6 months, HR 0.77 106
ALKALK-positive lung cancerCrizotinib cohort, 201082Response 57% 36
ALKALK-positive lung cancerCROWN, 7-year update 2026296Alive without progression at 7 years 55% vs 3%, HR 0.19 107
ROS1ROS1-rearranged lung cancerCrizotinib cohort, 201450Response 72% 88
RETRET fusion lung cancerLIBRETTO-001, 2020105 + 39Response 64% pretreated, 85% untreated 89
TRKTRK fusion cancers, 17 typesLarotrectinib, 201855Response 75% 95
HER2 and EGFRHER2-positive breast cancerLapatinib, 2006121 progression events at interim analysis 87Time to progression 8.4 vs 4.4 months 87
HER2 (mutant)HER2-mutant lung cancerBeamion LUNG-1, 2025-202675 + 74Response 71% pretreated, 76% untreated 108,109
FLT3Acute myeloid leukemiaRATIFY, 2017717Death HR 0.78 91
FLT3Relapsed acute myeloid leukemiaADMIRAL, 2019371Median survival 9.3 vs 5.6 months 92
KITGastrointestinal stromal tumorImatinib, 2002147Partial response 53.7% 90
VEGF and PDGF receptorsKidney cancerSunitinib, 2007750Progression-free 11 vs 5 months 94
VEGF and PDGF receptors, RAFLiver cancerSHARP, 2008602Median survival 10.7 vs 7.9 months 93
JAK1 and JAK2MyelofibrosisCOMFORT-I, 2012309Spleen response 41.9% vs 0.7% 83
BTKChronic lymphocytic leukemia, age 65+RESONATE-2, 2015269Progression or death HR 0.16 110

The words, defined

Non-small-cell lung cancer
The commonest group of lung cancers; adenocarcinoma, a cancer of the lung's gland-forming cells, is its largest type.
Somatic mutation
A change in DNA acquired in one tissue during life, not inherited and not passed to children.
Point mutation
A change of a single DNA letter, often swapping one amino acid for another.
Fusion gene
Two genes joined end to end by a chromosome break, making a hybrid protein.
Gastrointestinal stromal tumor
A tumor arising in the wall of the stomach or intestine rather than its lining.
Progression-free survival
The time a patient lives without the cancer growing or spreading.

JAK and BTK inhibitors, and the safety reversal of 2021

JAK2 entered cancer medicine through a single mutation. In 2005 V617F, a valine-to-phenylalanine change in the pseudo-kinase domain, was found in most patients with polycythemia vera; in a series of 244 patients with the three classic myeloproliferative neoplasms, chronic blood cancers that overproduce mature cells, it was present in 65% with polycythemia vera, 57% with idiopathic myelofibrosis and 23% with essential thrombocythemia 13,35; a more sensitive method found it in 97% of 73 patients with polycythemia vera 111. Ruxolitinib, which blocks JAK1 and JAK2, shrank the spleen by 35% or more in 41.9% of patients with myelofibrosis against 0.7% on placebo, and there were 13 deaths against 24 (hazard ratio 0.50, 95% confidence interval 0.25 to 0.98) 83. That trial was funded by Incyte, the drug's maker 83.

JAK inhibitors also act on the immune system, because the JAKs carry cytokine signals; losing JAK3 entirely causes severe immunodeficiency 32. Tofacitinib was approved for rheumatoid arthritis, and rises in blood lipids and in cancers on the drug prompted a post-authorization safety trial 22. ORAL Surveillance randomized 4,362 patients aged 50 or older with active rheumatoid arthritis and at least one additional cardiovascular risk factor to tofacitinib 5 mg or 10 mg twice daily or a TNF inhibitor, a biologic drug that blocks tumor necrosis factor, and followed them for a median of 4.0 years 22. Major adverse cardiovascular events, meaning heart attack, stroke or cardiovascular death, occurred in 3.4% on tofacitinib against 2.5% (hazard ratio 1.33, 95% confidence interval 0.91 to 1.94), and cancers other than non-melanoma skin cancer in 4.2% against 2.9% (hazard ratio 1.48, 1.04 to 2.09); noninferiority was not shown for either 22. Opportunistic infections, herpes zoster and non-melanoma skin cancer were also more common, while the drugs controlled arthritis equally well 22. The trial was open-label and funded by Pfizer, which makes tofacitinib 22.

The regulatory response came before the full publication 22,72. On 9 September 2021 the US Food and Drug Administration issued a drug safety communication and required revisions to the boxed warnings, its strongest label warning, that tofacitinib, baricitinib and upadacitinib already carried, adding serious heart-related events, cancer, blood clots and death; the warning rested on the tofacitinib trial, and neither of the other two drugs had been through a comparable one 72. It was a reversal in the plainest sense: tablets that had been tested against injected TNF inhibitors as equals for arthritis now carried a widened warning for harms the trial had found more often with them than with the injected drugs 22,72.

How far the warning should reach is still argued. A 2022 review concluded that the excess risk with tofacitinib concentrates in patients with existing cardiovascular disease or risk factors and that the evidence was insufficient to extend it to baricitinib and upadacitinib 112. A 2024 meta-analysis of 35 trials in skin diseases, with 20,651 younger patients followed for a mean of only 4.9 months, found no significant difference in a combined measure of major heart events and death from any cause (odds ratio 0.83, 95% confidence interval 0.44 to 1.57) or in venous clots (odds ratio 0.52, 0.26 to 1.04) 113; intervals that wide are compatible with modest harm as well as benefit, and short follow-up in a lower-risk population cannot answer a question about four years in an older, higher-risk one. A 2025 records study found fewer arterial clots and tuberculosis cases with topical ruxolitinib, which carries the same class warning, than with oral JAK inhibitors 114. In 2025 a JAK inhibitor, delgocitinib, was approved for hand eczema 21. The 2025 update of the European rheumatology recommendations still places JAK inhibitors after a biologic drug in rheumatoid arthritis, to be considered only after careful consideration of risks including heart events, cancers and blood clots 115. The systematic review behind it, of studies published from 2022 to January 2025, most of them observational and many built on insurance claims, found no consistent excess of major heart events with JAK inhibitors compared with biologic drugs, but a higher risk of venous clots, driven mainly by clots in the lungs, and more shingles; tuberculosis was not more common 116.

BTK took the opposite path, from a rare immune deficiency to a leukemia drug target 17,76. Chronic lymphocytic leukemia cells depend on signals from the B-cell receptor, which pass through BTK 76. Ibrutinib, which binds BTK covalently, forming a permanent chemical bond with one cysteine, produced responses in 71% of 85 patients with relapsed disease, with an estimated 26-month progression-free survival of 75% 76. In RESONATE-2, among 269 previously untreated patients aged 65 or older, it cut the risk of progression or death by 84% against chlorambucil and the risk of death by the same proportion (both hazard ratios 0.16), with 24-month survival of 98% against 85% 110. Both studies were funded by Pharmacyclics, the drug's developer, and others 76,110.

The permanent bond turned out to be breakable. In 2014, in five of six patients whose disease relapsed on ibrutinib, the cysteine the drug binds, C481, had mutated to serine, leaving a protein ibrutinib could block only reversibly; two had probable gain-of-function mutations in PLCG2 (phospholipase C gamma 2), the next link in the chain 46. Zanubrutinib, a BTK inhibitor with greater specificity, beat ibrutinib head to head in 652 relapsed patients (progression-free survival hazard ratio 0.65; 78.4% against 65.9% at 24 months) with fewer cardiac events, in a trial funded by its maker, BeiGene 84. Pirtobrutinib, a reversible, non-covalent inhibitor developed to get past those resistance mutations 117, produced responses in 62% of 121 patients already treated with a covalent BTK inhibitor and in 17 of 24 with a C481 mutation 85. The escape route moved rather than closed. In 2022, among 55 patients treated with pirtobrutinib, 9 who acquired resistance carried new mutations elsewhere in the BTK kinase domain (V416L, A428D, M437R, T474I and L528W) or in PLCG2, and in laboratory tests some of these mutations also defeated covalent BTK inhibitors 118.

The 2025 phase 3 trials, each with employees of Eli Lilly, the drug's maker, among the authors, tested where the non-covalent drug belongs. In BRUIN CLL-321, 238 patients already treated with a covalent BTK inhibitor were randomized to pirtobrutinib or the investigator's choice of idelalisib or bendamustine, each with rituximab: progression-free survival improved (hazard ratio 0.54; median 14 against 8.7 months), but overall survival did not differ (hazard ratio 1.09, 95% confidence interval 0.68 to 1.75) 119. In BRUIN CLL-313, 282 untreated patients were randomized to pirtobrutinib or bendamustine and rituximab: 24-month progression-free survival was 93.4% against 70.7% (hazard ratio 0.199), and an interim analysis of overall survival favored pirtobrutinib (hazard ratio 0.257, 95% confidence interval 0.070 to 0.934) although 52.9% of the comparison arm effectively crossed over to it 120. In BRUIN CLL-314, 662 patients who had never taken a BTK inhibitor were randomized to pirtobrutinib or ibrutinib; the response rate was noninferior, 87.0% against 78.5%, and atrial fibrillation, an irregular rapid heart rhythm, and high blood pressure were less common 121. CLL-321 and CLL-313 were open-label 119,120, and a 2026 systematic review summarizes all three 117. In BRUIN CLL-322, 639 previously treated patients were randomized to a fixed-duration course of venetoclax and rituximab with or without pirtobrutinib; adding it improved progression-free survival (hazard ratio 0.547; 87% against 72% at 24 months) without new safety signals, in an interim analysis of an open-label trial funded by Eli Lilly 74. BTK inhibitors have also left cancer: in 2025 remibrutinib was approved for chronic spontaneous urticaria, or hives, and rilzabrutinib for immune thrombocytopenia, a shortage of platelets caused by immune attack 21. They have also entered neurology. In HERCULES, 1,131 people with nonrelapsing secondary progressive multiple sclerosis were randomized two to one to tolebrutinib, a BTK inhibitor that enters the brain, or placebo; disability progression sustained for six months occurred in 22.6% against 30.7% (hazard ratio 0.69), while the liver enzyme ALT rose above three times normal in 4.0% against 1.6%, in a trial funded by its maker, Sanofi 122. A 2026 review notes that liver enzyme rises with these drugs can reach life-threatening levels 123.

The words, defined

JAK
Janus kinase: four non-receptor tyrosine kinases, JAK1, JAK2, JAK3 and TYK2, that act as the kinase for many cytokine receptors.
BTK
Bruton's tyrosine kinase, a non-receptor kinase in the B-cell receptor pathway; missing in X-linked agammaglobulinemia.
Covalent inhibitor
A drug that forms a permanent chemical bond with its target, here with cysteine 481 of BTK.
Non-covalent inhibitor
A drug that binds and lets go, without a permanent bond, and so does not depend on a particular cysteine.
Noninferiority trial
A trial designed to show that a treatment is not worse than another by more than an agreed margin; ORAL Surveillance's margin was a hazard ratio upper limit of 1.8.
Boxed warning
The strongest safety warning the US Food and Drug Administration places on a drug's label, printed inside a black border.
Myeloproliferative neoplasm
A chronic blood cancer in which the marrow overproduces mature red cells, platelets or white cells.
Odds ratio
The odds of an event in one group divided by the odds in another; like a hazard ratio, 1 means no difference.
Polycythemia vera
A chronic blood cancer in which the marrow makes too many red cells.
Essential thrombocythemia
A chronic blood cancer with too many platelets.
Myelofibrosis
A chronic blood cancer in which the marrow is replaced by scar tissue.
Chronic lymphocytic leukemia
A usually slow cancer of B cells in the blood, marrow and lymph nodes.
Atrial fibrillation
An irregular, often rapid heart rhythm that raises the risk of stroke.

What the drugs cost the body

Many tyrosine kinase inhibitor side effects are on-target: the drug blocks the same kinase in a healthy tissue that needs it. The clearest example is the skin. EGF receptor signaling maintains normal skin, and blocking it produces an acne-like rash that can be bad enough to interrupt cancer treatment 39; in IPASS, rash or acne affected 66.2% of patients on gefitinib 64. Drugs aimed at the VEGF receptors raise blood pressure: in a retrospective review of 75 patients with gastrointestinal stromal tumors on sunitinib, 47% developed hypertension above 150/100 mm Hg, 11% had a cardiovascular event and 8% heart failure 124. Grade 3 or worse hypertension affected 14% of patients on selpercatinib 89, and hypertension was the commonest cardiovascular event on osimertinib in a 2026 pooled analysis of 10,316 patients 125.

The QT interval, the time on the electrocardiogram the heart's ventricles take to recharge between beats, is lengthened by several of these drugs, which raises the risk of a dangerous rhythm 126. In thyroid cancer, QT prolongation was the most frequent adverse event of vandetanib in a meta-analysis of 34 studies 127; on osimertinib, QT prolongation of any grade occurred in 6.88% overall and was more common when chemotherapy was added 125. The European cardio-oncology guideline sets out electrocardiogram (ECG), blood pressure and heart-function monitoring for these drugs 126.

Heart muscle damage is the most contested effect. In 2006 a report described ten patients who developed severe heart failure on imatinib, with mitochondrial damage in their heart tissue and the same damage in treated mice and cultured heart cells, and argued it was a direct result of blocking ABL 40. The IRIS investigators, with almost eleven years of follow-up, reported that long-term imatinib was not associated with unacceptable cumulative or late toxic effects 20. Both can be true, a rare effect in susceptible patients and a low rate overall, and a case series cannot settle which 20,40. The alarm was tested within a year: investigators at the M. D. Anderson Cancer Center reviewed serious cardiac events among 1,276 patients enrolled in imatinib trials and found 22 (1.7%) with symptoms that could be attributed to heart failure, 8 (0.6%) judged possibly or probably caused by the drug, mostly in older people with existing heart disease 128. The vascular harm of ponatinib is not contested: it is dose-dependent and was common enough to change how the drug is dosed 66,100. Dasatinib can cause pulmonary arterial hypertension, high pressure in the lung's arteries; the French registry found nine cases, an estimated incidence of at least 0.45%, and most patients improved without fully recovering after the drug was stopped 129. Second-generation drugs carry their own vascular cost. In ENESTnd, by ten years cardiovascular events had occurred in 16.5% and 23.5% of patients on the two nilotinib doses against 3.6% on imatinib, including patients at low predicted cardiovascular risk, while estimated ten-year survival was similar, 87.6%, 90.3% and 88.3%; several of the authors were Novartis employees 130.

Bleeding and heart rhythm problems are the side effects against which ibrutinib's successors have been measured. In RESONATE-2, four patients had grade 3 and one a grade 4 hemorrhage on ibrutinib 110; zanubrutinib caused fewer cardiac events than ibrutinib head to head 84, and pirtobrutinib markedly less atrial fibrillation 117. JAK inhibitors add infections, including shingles and tuberculosis among the opportunistic infections counted in ORAL Surveillance 22.

The words, defined

On-target toxicity
A side effect caused by blocking the intended target in a healthy tissue, not by hitting something else.
QT interval
The stretch of the electrocardiogram from the start of the ventricles' electrical activation to the end of their recovery; long QT predisposes to dangerous rhythms.
Ejection fraction
The share of blood the left ventricle pumps out with each beat; a fall signals weakened heart muscle.
Pulmonary arterial hypertension
High blood pressure in the arteries of the lungs, which strains the right side of the heart.

What the drugs cost the purse

A drug taken daily for decades by people who now live almost a normal life span is expensive in a new way. The Swedish registry authors pointed out that as patients with chronic myeloid leukemia live longer, the number living with the disease grows, and health care costs grow with it as long as continuous treatment is required 28. In 2013 more than 100 specialists in the disease published a joint statement in Blood arguing that the prices of tyrosine kinase inhibitors for chronic myeloid leukemia reflected unsustainable cancer drug pricing, and calling for lower prices so that more patients could afford them 131.

Generic imatinib did less than hoped. An analysis of US claims data found few manufacturers entering the market, price reductions smaller than expected, prescribing shifting toward more expensive brand-name drugs, and limited uptake of the generic 132. Stopping treatment is the other saving: EURO-SKI estimated that discontinuation saved about 22 million euros across its patients 23. National data now show the same pattern. In Dutch hospital claims from 2013 to 2022, after imatinib lost market exclusivity in 2017, total spending on imatinib fell by 95% and reimbursement per treated patient-year by 89%, but the prices of the patented alternatives, dasatinib and nilotinib, showed little or no fall toward it, so substantial potential savings went unrealized 133.

The prices themselves differ several-fold 134. A 2026 US analysis using list wholesale prices and label doses estimated the yearly cost of treatment in 2025 at about $22,430 for imatinib, averaged across generic and brand-name products, $72,693 for dasatinib, $89,138 for nilotinib and more than $100,000 for each of the other later drugs; it was a model, not a survey of what patients paid, and two of its authors were Novartis employees 134. A 2025 review by leukemia specialists notes that generic imatinib can cost less than $1,000 a year worldwide, while second-generation drugs, even as generics, remain too expensive in the United States to offer good value 135.

The insulin receptor: a tyrosine kinase at the center of metabolism

The receptor tyrosine kinase best known outside oncology is insulin's. In 1982 insulin was shown to make its receptor phosphorylate itself on tyrosine in rat liver membranes 25, and in 1985 the human receptor's 1,370-amino-acid precursor was sequenced: a signal sequence, an alpha subunit outside the cell, a cleavage site, and a beta subunit with a single membrane-crossing segment and a kinase related to the EGF receptor and the src family 10. Insulin's message into the cell begins as tyrosine phosphorylation, and Hunter lists metabolic regulation through the insulin receptor among the many processes tyrosine phosphorylation governs 4.

That does not make common insulin resistance a fault in the receptor's gene. Insulin resistance is most often found with obesity; an unusually severe form occurs in rare patients with single-gene defects, some in insulin signaling itself and some in fat tissue, and these are biochemically and clinically distinct from the common condition 34. In the common form the signal still starts at the tyrosine kinase, but the explanations most studied place the problem downstream of it: fats such as diacylglycerol and ceramide accumulating in muscle and liver, stress in the endoplasmic reticulum and mitochondria, and inflammatory and other circulating signals, each argued for and against in the literature 136.

Tyrosine kinase inhibitors have been tried in diabetes too, from the immune side. In a 2021 phase 2 trial, 67 adults with recent-onset type 1 diabetes were randomized two to one to imatinib or placebo for 26 weeks; at 12 months the imatinib group had preserved slightly more of its own insulin production, measured as C-peptide, a fragment released in equal amounts with the body's own insulin (adjusted difference 0.095, 90% confidence interval -0.003 to 0.191, one-tailed p = 0.048), and the effect was gone by 24 months 137. A one-tailed test with a 90% interval is a lenient standard, and the result is a reason for further trials, not a treatment 137.

'Natural tyrosine kinase inhibitors': genistein, curcumin, green tea

The phrase has a real origin. In 1987 Akiyama and colleagues reported that genistein, an isoflavone abundant in soybeans, inhibited the tyrosine kinase activity of the EGF receptor, of v-src and of another viral kinase in a test tube, competing with ATP, while scarcely touching several serine and threonine kinases; in cultured A431 cells it reduced the EGF-stimulated rise in phosphotyrosine 29. What the paper shows is an effect in purified enzymes and cultured cells, at concentrations chosen in the laboratory.

What reaches the blood is the question. In six men who ate a soy-flour meal, plasma genistein peaked at 4.09 micromoles per liter about eight hours later 30. Whether that is enough to inhibit any tyrosine kinase in a human tissue has not been shown in the sources found for this page, and no randomized trial among them shows soy or a genistein supplement acting as a tyrosine kinase inhibitor in a person 29,30. The supplements are also unreliable carriers: an analysis of 33 commercial phytoestrogen supplements found isoflavone contents differing considerably from what the manufacturers claimed 138.

Curcumin, from turmeric, is the weakest case of the three. A 2017 review by medicinal chemists concluded that curcumin is unstable, chemically reactive and poorly absorbed, that it is flagged as a pan-assay interference compound, a molecule that gives false positive results across many laboratory tests, and that despite more than 120 clinical trials, no double-blind, placebo-controlled trial of curcumin had succeeded 31. On this evidence, a list of kinases curcumin inhibits in a test tube says more about the assays than about any patient 31. That verdict needs one qualification. In 2020 a double-blind, placebo-controlled trial in 70 adults with painful knee osteoarthritis found that a turmeric (Curcuma longa) extract reduced knee pain by 9.1 millimeters more than placebo on a visual pain scale, without changing joint swelling on magnetic resonance imaging or cartilage composition; it was small, lasted 12 weeks, was co-funded by a company, Natural Remedies Private Limited, and measured pain, not any kinase 139. A modest symptom effect in one trial is not evidence that curcumin inhibits a tyrosine kinase in a person.

Green tea has been tested in people, and the results cut both ways. In a phase 1 trial at the Mayo Clinic, 33 patients with early, untreated chronic lymphocytic leukemia took Polyphenon E, a standardized green tea catechin extract rich in EGCG, at doses up to 2,000 mg twice a day 140. One had a partial remission by formal criteria, a third had a sustained fall of at least 20% in lymphocyte count, and 11 of 12 with enlarged lymph nodes saw them shrink by at least half; a third also had mild liver enzyme rises, and trough blood EGCG levels, measured just before the next dose, varied more than a thousandfold, from 2.9 to 3,974 ng/mL 140. There was no control group 140. A phase 2 trial in 42 patients at the top dose, again without a control group, reported a sustained fall of at least 20% in lymphocyte count in 31% and at least a halving of lymph node size in 20 of 29 with enlarged nodes 141. In the Minnesota Green Tea Trial, 1,075 postmenopausal women were randomized to green tea extract supplying 843 mg of EGCG a day or placebo for a year; ALT, a liver enzyme, rose in 6.7% on the extract against 0.7% on placebo, and 1.3% had serious adverse events related to it 142. A later secondary analysis found that in women with one variant of a glucuronosyltransferase gene, which helps clear EGCG, ALT rose by 78.1% at month 6 against 28.0% in the other genotype 143. Concentrated green tea catechins are pharmacologically active, and at high doses that includes the liver 143.

The traffic also runs the other way. Dasatinib, a prescription tyrosine kinase inhibitor, has been combined with quercetin, a plant flavonoid sold as a supplement, as a senolytic, a treatment meant to clear aged, senescent cells 144. In the first human pilot, 14 patients with idiopathic pulmonary fibrosis, progressive scarring of the lungs of unknown cause, took the pair three days a week for three weeks in an open-label study; walking distance and gait speed improved, while lung function did not change 144. It was a feasibility study, and its authors called for randomized trials 144. The first randomized test came in 2024: in a phase 2 trial in 60 postmenopausal women, intermittent dasatinib and quercetin did not reduce the primary blood marker of bone breakdown at 20 weeks; a marker of bone formation rose briefly, and exploratory analyses suggested effects only in women with the most senescent cells 145.

The words, defined

Isoflavone
A class of plant compounds, abundant in soy, that includes genistein and daidzein; some act weakly like estrogen.
Pan-assay interference compound
A molecule that gives false positive results in many laboratory screens by reacting, aggregating or interfering with the readout rather than by acting specifically.
EGCG
Epigallocatechin gallate, the main catechin in green tea and the active ingredient of concentrated green tea extracts.
Senolytic
A drug meant to kill senescent cells, cells that have stopped dividing but persist and release inflammatory signals.
In vitro
In a test tube or culture dish, outside a living body; such results show what a molecule can do, not what it does in a person.

What was believed and is not

That the src kinase phosphorylated threonine. It was the first published answer, and within a year or two the laboratory that set out to find the same thing in another virus found tyrosine instead 9,57.

That inhibitors aimed at the ATP site, which every kinase shares, would be too unselective to make good drugs. Making drug-like inhibitors did prove difficult for years 4, but imatinib's structure showed that a drug can recognize the particular way one kinase switches itself off, achieving both affinity and specificity 43, more than 70 kinase drugs were approved in the twenty years after imatinib 146, and by 2026 there were 94 approved kinase inhibitors in the United States 21.

That an EGFR inhibitor is a lung cancer drug. Approved for lung cancer without regard to tumor genetics in 2003 62, gefitinib did not lengthen survival overall 70 and was worse than chemotherapy without the mutation 64; in 2015 it was approved again for EGFR-mutant tumors only 71.

That treatment of chronic myeloid leukemia is for life. About half of patients in sustained deep remission stay in remission after stopping, in trials that selected them carefully and watched them closely 23,24.

That a deeper molecular response means a longer life. Nilotinib produced deeper responses than imatinib and more patients eligible to stop, but similar ten-year survival and more heart and artery events 130.

That a permanent bond means permanent inhibition, and that a drug without the bond escapes resistance. Cancer cells changed the cysteine ibrutinib bonds to 46, a non-covalent drug was built that does not need it 85, and leukemias then escaped that drug through other changes in the kinase domain 118.

That a resistant leukemia needs the highest tolerated dose throughout. Ponatinib's arterial toxicity rose with dose, and the best balance came from starting high and cutting the dose on response 66,100,101.

That a JAK inhibitor tablet was as safe as an injected TNF inhibitor for arthritis. In older patients with cardiovascular risk factors, tofacitinib could not be shown to be 22, and the label changed 72.

That foods are natural tyrosine kinase inhibitors in any clinical sense. The evidence is enzyme and cell-culture work, with no trial among the sources found showing such an effect in people, and with curcumin the laboratory signal itself is suspect 29,31.

That the first tyrosine kinase behind an inherited disease was BTK. Its discoverers claimed a first only for a src-related gene 17; insulin receptor mutations had been found in 1988 77,78 and a KIT mutation in 1991 79.

What is strange about them

A bird virus carries a stolen growth factor receptor. The v-erbB cancer protein of avian erythroblastosis virus matched the human EGF receptor at 74 of 83 amino acids sampled, and appears to be a version of the receptor with its EGF-binding part cut off 59.

The mutation that switches on JAK2 in polycythemia vera is not in the kinase domain at all. It is in the pseudo-kinase domain next to it, a domain shaped like a kinase but without its catalytic role, and the change there leaves the real kinase constantly active 35.

Imatinib's chemical scaffold came from a protein kinase C program, and its first tyrosine kinase target was the PDGF receptor, to prevent the re-narrowing of arteries, not leukemia 4.

Tyrosine phosphorylation is older than animals. Choanoflagellates, single-celled relatives of animals, have 128 predicted tyrosine kinases, a network as complex as ours, though only seven are counterparts of animal kinases 1,4.

The mark these enzymes make accounts for under 1% of the phosphate on a cell's proteins 4, yet 74 of the 94 kinase inhibitors approved in the United States are aimed at them 21.

What is still unknown

Who can stop treatment safely, and for how long. In J-SKI the only independent predictor of a lasting treatment-free remission was the duration of deep molecular response before stopping 24, and late relapse with progression is documented in at least one patient who declined to restart 104. Whether a newer drug such as asciminib lets more people stop is not yet answered; the first-line asciminib evidence reviewed in 2026 reports molecular responses, not stopping 103. Why stopping works at all is itself unexplained: in laboratory work on cells from newly diagnosed patients, the most primitive leukemic stem cells survived imatinib when given growth factors, even though BCR-ABL was fully inhibited, which predicts that the drug alone does not eradicate the disease 147.

Whether asciminib's better molecular responses become longer lives. ASC4FIRST measured molecular response, not survival, and was not designed to compare asciminib directly with second-generation drugs 45. The precedent is cautionary: in ENESTnd, nilotinib gave higher ten-year rates of major molecular response than imatinib (77.7% and 79.7% against 62.5%) without a clear difference in ten-year survival 130.

How far the JAK warning should reach. The trial that prompted it studied one drug in older patients with rheumatoid arthritis and cardiovascular risk factors 22; whether the same risk applies to other JAK inhibitors, to younger patients with skin disease, or to creams, rests on shorter trials and observational data 112,113,114.

Whether non-covalent BTK inhibition lengthens life. After covalent inhibitors it did not in BRUIN CLL-321 (hazard ratio 1.09) 119; in untreated patients an interim analysis favored it, on few deaths and with wide uncertainty 120.

How much of the rare heart failure on imatinib the drug causes: a convincing case series 40 was followed by a trial-based estimate of 0.6% possibly or probably related 128 and reassuring long-term data 20, but no comparison was ever designed to measure it.

Whether any of the immune or senolytic uses of these drugs will survive randomized trials of meaningful size: imatinib in type 1 diabetes met only a lenient threshold, and the effect faded 137; the first randomized trial of dasatinib with quercetin, in bone, missed its primary end point 145, and the lung fibrosis pilot had no control group 144.

Where it connects

On the map

A star in Oncogenes, one of 3. The enzymes that pass a growth signal on by tagging proteins at tyrosine; jammed on, they drive leukemias and lung cancers, and imatinib proved a pill could switch one off

Find it on the map

Sources

148 sources, numbered as they are cited. Every one was checked against PubMed or its publisher before it was cited here; the note under each says what it shows and what it does not.

  1. 1
    Hunter T. The genesis of tyrosine phosphorylation.Cold Spring Harb Perspect Biol · 2014 · 6(5):a020644doi:10.1101/cshperspect.a020644 · PMID 24789824

    Review of the evolution and function of tyrosine phosphorylation, arguing that its main job is to create docking sites for SH2 and PTB domains.

  2. 2
    Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems.Cell · 2004 · 116(2):191-203doi:10.1016/s0092-8674(03)01077-8 · PMID 14744431

    Pawson's review of how phosphotyrosine sites bind SH2 domains and how modular binding builds signaling pathways. A review.

  3. 3
    Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome.Oncogene · 2000 · 19(49):5548-57doi:10.1038/sj.onc.1203957 · PMID 11114734

    The 2000 census, two years before the full kinome: 90 tyrosine kinase genes and five pseudogenes, 58 receptor-type in 20 subfamilies and 32 non-receptor in 10.

  4. 4
    Hunter T. Tyrosine phosphorylation: thirty years and counting.Curr Opin Cell Biol · 2009 · 21(2):140-6doi:10.1016/j.ceb.2009.01.028 · PMID 19269802

    A personal review by the discoverer, read in full: the 1979 discovery, the receptor and non-receptor classes, 90 of 525 human kinase genes, 51 of the 90 implicated in cancer, phosphotyrosine under 1% of protein phosphate, the origin of imatinib, and the gatekeeper mutations. A review, not primary data.

  5. 5
    Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.Proc Natl Acad Sci U S A · 2010 · 107(17):7692-7doi:10.1073/pnas.1002753107 · PMID 20351256

    Test-tube, crystal and simulation work: the supposedly dead ERBB3 kinase binds ATP and trans-autophosphorylates, far more weakly than EGFR, and does not phosphorylate exogenous peptides.

  6. 6
    Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome.Science · 2002 · 298(5600):1912-34doi:10.1126/science.1075762 · PMID 12471243

    The human kinome: 518 protein kinase genes and 106 pseudogenes, with 244 kinases mapping to disease loci or cancer amplicons. The first author was at SUGEN Inc., a kinase-drug company.

  7. 7
    Sadowski I, Stone JC, Pawson T. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps.Mol Cell Biol · 1986 · 6(12):4396-408doi:10.1128/mcb.6.12.4396-4408.1986 · PMID 3025655

    The description of the roughly 100-residue noncatalytic domain next to the 260-residue kinase domain of cytoplasmic tyrosine kinases, later called SH2. Rat cells and bacteria; it does not yet show that the domain binds phosphotyrosine.

  8. 8
    Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia.Cell · 1993 · 72(2):279-90doi:10.1016/0092-8674(93)90667-f · PMID 8425221

    The same kinase found independently, with SH1 (kinase), SH2 and SH3 domains, and reduced or absent in XLA B cells.

  9. 9
    Hunter T, Sefton BM. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.Proc Natl Acad Sci U S A · 1980 · 77(3):1311-5doi:10.1073/pnas.77.3.1311 · PMID 6246487

    The paper that showed pp60src is a tyrosine kinase: up to 8-fold more phosphotyrosine in transformed chicken cells, and the normal cellular protein phosphorylating tyrosine too. Cell and test-tube work, not a disease study.

  10. 10
    Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.Nature · 1985 · 313(6005):756-61doi:10.1038/313756a0 · PMID 2983222

    The full 1,370-amino-acid sequence of the human insulin receptor precursor, with homology to the EGF receptor and the src family. Sequence work; Genentech-affiliated authors.

  11. 11
    Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.Science · 1990 · 247(4944):824-30doi:10.1126/science.2406902 · PMID 2406902

    Mouse marrow carrying P210 BCR-ABL produced a disease closely resembling chronic-phase CML: the evidence that the fusion kinase is a cause, not a marker. Mouse work. The abstract itself calls the Philadelphia chromosome "a fusion of chromosomes 9 and 22"; it is more exactly one product of a reciprocal translocation [25].

  12. 12
    Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.Cell · 1984 · 36(1):93-9doi:10.1016/0092-8674(84)90077-1 · PMID 6319012

    Breakpoints in 17 of 19 CML patients fell within a 5.8-kb region they named the breakpoint cluster region, bcr; the two without lacked the Philadelphia chromosome.

  13. 13
    Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders.N Engl J Med · 2005 · 352(17):1779-90doi:10.1056/NEJMoa051113 · PMID 15858187

    244 patients: V617F in 65% with polycythemia vera, 57% with idiopathic myelofibrosis and 23% with essential thrombocythemia.

  14. 14
    Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.Nature · 1993 · 363(6428):458-60doi:10.1038/363458a0 · PMID 8099202

    RET missense mutations in 20 of 23 MEN 2A families and none of 23 controls; the gene lies on chromosome 10q11.2.

  15. 15
    Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia.Cell · 1994 · 78(2):335-42doi:10.1016/0092-8674(94)90302-6 · PMID 7913883

    The glycine-to-arginine change at position 380 of FGFR3 on all 16 achondroplasia chromosomes studied: 15 by a G-to-A and one by a G-to-C change at nucleotide 1138. Genetics only; it does not show that the receptor is activated.

  16. 16
    Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature · 2007 · 448(7153):561-6doi:10.1038/nature05945 · PMID 17625570

    A small inversion on chromosome 2p fuses EML4 to ALK; found in 5 of 75 (6.7%) lung cancers and transforming in mouse cells.

  17. 17
    Vetrie D, Vorechovský I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.Nature · 1993 · 361(6409):226-33doi:10.1038/361226a0 · PMID 8380905

    Identification of the X-linked agammaglobulinemia gene, later named BTK, as a src-family tyrosine kinase; the abstract calls it the first evidence that mutations in a src-related gene cause human genetic disease. Insulin receptor (1988) and KIT (1991) mutations in inherited disease came earlier [112][113][114].

  18. 18
    Eckhart W, Hutchinson MA, Hunter T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates.Cell · 1979 · 18(4):925-33doi:10.1016/0092-8674(79)90205-8 · PMID 229973

    The first report of a tyrosine-phosphorylating activity, found in immunoprecipitates of polyomavirus middle T antigen. The kinase turned out to be a cellular one bound to middle T, which the paper could not yet say.

  19. 19
    Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.Nat Rev Drug Discov · 2002 · 1(7):493-502doi:10.1038/nrd839 · PMID 12120256

    The development story told by the Novartis team that made the drug. Commercial authorship; a narrative review.

  20. 20
    Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.N Engl J Med · 2017 · 376(10):917-927doi:10.1056/NEJMoa1609324 · PMID 28273028

    IRIS at a median 10.9 years: 10-year overall survival 83.3% in the imatinib arm. Because 65.6% of the comparison arm crossed over, it cannot show a survival difference between the arms. Funded by Novartis.

  21. 21
    Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.Pharmacol Res · 2026 · 224:108107doi:10.1016/j.phrs.2026.108107 · PMID 41587611

    Annual census: 94 FDA-approved protein kinase inhibitors, 48 aimed at receptor and 26 at non-receptor tyrosine kinases, ten approved in 2025. A review; its abstract describes sunvozertinib's target as an exon 21 insertion, which appears to be an error for exon 20.

  22. 22
    Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.N Engl J Med · 2022 · 386(4):316-326doi:10.1056/NEJMoa2109927 · PMID 35081280

    ORAL Surveillance, 4,362 patients aged 50 or older with a cardiovascular risk factor: tofacitinib failed to meet noninferiority against TNF inhibitors for heart events (HR 1.33) and cancer (HR 1.48). Open-label; required by regulators; funded by Pfizer.

  23. 23
    Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.Lancet Oncol · 2018 · 19(6):747-757doi:10.1016/S1470-2045(18)30192-X · PMID 29735299

    758 patients in 11 countries: molecular relapse-free survival 61% at 6 months and 50% at 24 months; an estimated 22 million euros saved. Non-randomized.

  24. 24
    Takahashi N, Kimura S, Matsuki E, et al. Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan.Int J Hematol · 2026 · 124(1):96-103doi:10.1007/s12185-026-04184-4 · PMID 41764681

    795 Japanese patients: 5-year treatment-free remission 65.2%; 99% of those who relapsed regained major molecular response. Observational, partly retrospective.

  25. 25
    Kasuga M, Zick Y, Blithe DL, Crettaz M, Kahn CR. Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system.Nature · 1982 · 298(5875):667-9doi:10.1038/298667a0 · PMID 6178977

    The insulin receptor phosphorylates itself on tyrosine when insulin binds, in rat liver membranes. No abstract is indexed; the claim rests on the title.

  26. 26
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med · 2004 · 350(21):2129-39doi:10.1056/NEJMoa040938 · PMID 15118073

    EGFR kinase-domain mutations in 8 of 9 gefitinib responders and none of 7 non-responders. Small, retrospective.

  27. 27
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.Science · 1998 · 279(5350):577-80doi:10.1126/science.279.5350.577 · PMID 9438854

    KIT mutations in five GISTs made the receptor active without its ligand and transformed mouse cells.

  28. 28
    Bower H, Björkholm M, Dickman PW, et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.J Clin Oncol · 2016 · 34(24):2851-7doi:10.1200/JCO.2015.66.2866 · PMID 27325849

    Swedish Cancer Registry, 2,662 patients 1973-2013: those diagnosed in 2013 lose on average fewer than 3 life-years. Population data; it attributes the gain to TKIs along with transplantation and other factors.

  29. 29
    Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases.J Biol Chem · 1987 · 262(12):5592-5PMID 3106339

    The soy isoflavone genistein inhibited EGF receptor, v-src and gag-fes kinases in a test tube, competing with ATP, and scarcely touched serine/threonine kinases. In vitro and cell-line work only; no DOI is indexed.

  30. 30
    King RA, Bursill DB. Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans.Am J Clin Nutr · 1998 · 67(5):867-72doi:10.1093/ajcn/67.5.867 · PMID 9583843

    Six men: plasma genistein peaked at 4.09 micromoles per liter about 8.4 hours after a soy-flour meal.

  31. 31
    Nelson KM, Dahlin JL, Bisson J, et al. The Essential Medicinal Chemistry of Curcumin.J Med Chem · 2017 · 60(5):1620-1637doi:10.1021/acs.jmedchem.6b00975 · PMID 28074653

    Medicinal chemists' review: curcumin is unstable, reactive and poorly absorbed, flagged as a pan-assay interference compound, and no double-blind placebo-controlled trial of it had succeeded.

  32. 32
    Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID).Nature · 1995 · 377(6544):65-8doi:10.1038/377065a0 · PMID 7659163

    Two unrelated children with T-cell-negative, B-cell-positive SCID, each with homozygous JAK3 mutations. Two cases; the mechanism, not the frequency.

  33. 33
    Indo Y, Tsuruta M, Hayashida Y, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis.Nat Genet · 1996 · 13(4):485-8doi:10.1038/ng0896-485 · PMID 8696348

    Kinase-domain mutations in TRKA in three unrelated patients who felt no pain and did not sweat. Three cases.

  34. 34
    Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S. Genetic syndromes of severe insulin resistance.Endocr Rev · 2011 · 32(4):498-514doi:10.1210/er.2010-0020 · PMID 21536711

    Review of rare monogenic severe insulin resistance, including primary disorders of insulin signaling, set against the common, obesity-related kind.

  35. 35
    James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.Nature · 2005 · 434(7037):1144-8doi:10.1038/nature03546 · PMID 15793561

    JAK2 V617F, in the pseudo-kinase domain, in more than 80% of their polycythemia vera patients; it causes erythrocytosis in mice.

  36. 36
    Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med · 2010 · 363(18):1693-703doi:10.1056/NEJMoa1006448 · PMID 20979469

    About 1,500 tumors screened to find 82 ALK-positive patients; crizotinib response rate 57%. Single-arm; funded by Pfizer and others.

  37. 37
    Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B.Science · 1995 · 267(5196):381-3doi:10.1126/science.7824936 · PMID 7824936

    MEN2A and MEN2B RET alleles transformed NIH 3T3 cells through constitutive activation of the RET kinase; the MEN2A mutation caused RET dimerization. Cell work.

  38. 38
    Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.Nat Genet · 1996 · 13(2):233-7doi:10.1038/ng0696-233 · PMID 8640234

    G380R and the thanatophoric dysplasia mutations each activated FGFR3 without ligand, the lethal ones more strongly. Cell work.

  39. 39
    Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors.Nat Rev Cancer · 2006 · 6(10):803-12doi:10.1038/nrc1970 · PMID 16990857

    Review explaining the rash of EGFR inhibitors as on-target inhibition in skin that depends on EGFR signaling.

  40. 40
    Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.Nat Med · 2006 · 12(8):908-16doi:10.1038/nm1446 · PMID 16862153

    Ten patients with severe heart failure on imatinib, plus heart damage in treated mice and cultured heart cells. A case series and laboratory work; it cannot give a rate.

  41. 41
    Hunter T. A journey from phosphotyrosine to phosphohistidine and beyond.Mol Cell · 2022 · 82(12):2190-2200doi:10.1016/j.molcel.2022.05.007 · PMID 35654043

    Review: nine of the 20 amino acids in proteins can be phosphorylated; most knowledge concerns serine, threonine and tyrosine.

  42. 42
    Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases.Cell · 2010 · 141(7):1117-34doi:10.1016/j.cell.2010.06.011 · PMID 20602996

    Review of receptor tyrosine kinase activation, emphasizing that the ways ligands induce dimerization are surprisingly diverse.

  43. 43
    Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.Science · 2000 · 289(5486):1938-42doi:10.1126/science.289.5486.1938 · PMID 10988075

    The crystal structure: imatinib binds Abl only in an inactive shape with an unphosphorylated activation loop, which explains its selectivity.

  44. 44
    Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.Nature · 2017 · 543(7647):733-737doi:10.1038/nature21702 · PMID 28329763

    Asciminib binds the myristoyl pocket, away from the ATP site, and has a resistance pattern that does not overlap with nilotinib's; the combination eradicated xenografts in mice. Laboratory and mouse work by the developing company's scientists.

  45. 45
    Hochhaus A, Wang J, Kim DW, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.N Engl J Med · 2024 · 391(10):885-898doi:10.1056/NEJMoa2400858 · PMID 38820078

    ASC4FIRST, 405 patients: major molecular response at week 48, 67.7% versus 49.0% with investigator-chosen TKIs, driven by the imatinib comparison; the difference against second-generation drugs was not significant and was not a primary objective. Funded by Novartis. A response end point, not survival.

  46. 46
    Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.N Engl J Med · 2014 · 370(24):2286-94doi:10.1056/NEJMoa1400029 · PMID 24869598

    In 5 of 6 relapsing patients, a cysteine-to-serine change at the drug's binding site (C481S) made the bond reversible; PLCG2 mutations in 2. Small series.

  47. 47
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.Science · 2001 · 293(5531):876-80doi:10.1126/science.1062538 · PMID 11423618

    In 6 of 9 relapsing patients a single threonine-to-isoleucine change in the drug's binding site (later called T315I); in 3, more copies of BCR-ABL. Small series of advanced disease.

  48. 48
    Hunter T. The epidermal growth factor receptor-the prototypic RTK-turns 40.Philos Trans R Soc Lond B Biol Sci · 2026 · 381(1957)doi:10.1098/rstb.2024.0495 · PMID 42656153

    A 2026 historical review of how the study of viral transforming proteins and of growth factor receptors converged on the receptor tyrosine kinase. History, not new data.

  49. 49
    Nowell PC. Discovery of the Philadelphia chromosome: a personal perspective.J Clin Invest · 2007 · 117(8):2033-5doi:10.1172/JCI31771 · PMID 17671636

    Nowell's account of finding, with David Hungerford, an abnormally small chromosome in CML cells. The original 1960 report in Science was not found in PubMed and was not opened.

  50. 50
    Nowell PC. The minute chromosome (Phl) in chronic granulocytic leukemia.Blut · 1962 · 8:65-6doi:10.1007/BF01630378 · PMID 14480647

    An early follow-up note using the name Ph1. No abstract is indexed.

  51. 51
    Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.J Biol Chem · 1962 · 237:1555-62PMID 13880319

    The isolation of the protein later named epidermal growth factor. No abstract or DOI is indexed; the description rests on the title. Mouse work.

  52. 52
    Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.Nature · 1973 · 243(5405):290-3doi:10.1038/243290a0 · PMID 4126434

    Rowley's banding study, the first to see the consistent chromosome exchange behind the Philadelphia chromosome. No abstract is indexed.

  53. 53
    Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA.Nature · 1976 · 260(5547):170-3doi:10.1038/260170a0 · PMID 176594

    The finding that the cancer gene of Rous sarcoma virus has a counterpart in the DNA of normal birds, so that the virus had picked it up from a cell. No abstract is indexed; the claim rests on the title and the paper. It says nothing yet about what the gene's protein does.

  54. 54
    Larsen CJ. [The Nobel Prize in physiology and medicine 1989. J. Michael Bishop and Harold E. Varmus].Pathol Biol (Paris) · 1989 · 37(10):1077-8PMID 2608316

    Editorial in French recording the 1989 prize; no abstract or DOI indexed, and the claim rests on the title.

  55. 55
    Bishop JM. Nobel Lecture. Retroviruses and oncogenes II.Biosci Rep · 1990 · 10(6):473-91doi:10.1007/BF01116609 · PMID 1964811

    Bishop's Nobel lecture on the cellular origin of retroviral oncogenes. A personal review, not new data.

  56. 56
    Varmus HE. Nobel lecture. Retroviruses and oncogenes. I.Biosci Rep · 1990 · 10(5):413-30doi:10.1007/BF01152288 · PMID 1704261

    Varmus's companion Nobel lecture. A personal review, not new data.

  57. 57
    Hunter T. Discovering the first tyrosine kinase.Proc Natl Acad Sci U S A · 2015 · 112(26):7877-82doi:10.1073/pnas.1508223112 · PMID 26130799

    Hunter's own retrospective. The abstract records Erikson's earlier report that the src kinase was threonine-specific, calls the middle T tyrosine finding serendipitous and the v-Src observation that followed fortuitous, and says the 1980 experiments took less than a month. No PMC full text was available; the buffer anecdote is sourced to [105] instead.

  58. 58
    Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.J Biol Chem · 1980 · 255(18):8363-5PMID 6157683

    Showed that the kinase switched on by EGF in membranes of a human carcinoma cell line phosphorylates tyrosine, and that the purified receptor complex does so itself. Test-tube and cell-line work; no DOI is indexed.

  59. 59
    Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.Nature · 1984 · 307(5951):521-7doi:10.1038/307521a0 · PMID 6320011

    74 of 83 amino acids in six EGF receptor peptides matched the v-erbB protein of avian erythroblastosis virus: the virus carries a truncated receptor without its EGF-binding part.

  60. 60
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.Nat Med · 1996 · 2(5):561-6doi:10.1038/nm0596-561 · PMID 8616716

    The compound later named imatinib cut BCR-ABL colonies from CML patients' marrow and blood by 92-98% without inhibiting normal colonies. Laboratory work; several authors were Ciba-Geigy scientists.

  61. 61
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med · 2001 · 344(14):1031-7doi:10.1056/NEJM200104053441401 · PMID 11287972

    The phase 1 trial in 83 patients after interferon had failed: complete blood responses in 53 of 54 at 300 mg or more. Dose-finding, not a comparison with other treatment.

  62. 62
    Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.Clin Cancer Res · 2004 · 10(4):1212-8doi:10.1158/1078-0432.ccr-03-0564 · PMID 14977817

    FDA staff summary: accelerated approval 5 May 2003 on a 10.6% response rate in 142 patients; two trials of 1,093 and 1,037 patients showed no benefit from adding gefitinib to chemotherapy.

  63. 63
    Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science · 2004 · 304(5676):1497-500doi:10.1126/science.1099314 · PMID 15118125

    EGFR mutations in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States, matching where gefitinib worked.

  64. 64
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med · 2009 · 361(10):947-57doi:10.1056/NEJMoa0810699 · PMID 19692680

    IPASS, 1,217 East Asian non-smokers or light smokers: gefitinib better if EGFR was mutated (HR 0.48) and worse if it was not (HR 2.85). Open-label.

  65. 65
    Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.Lancet Oncol · 2010 · 11(11):1029-35doi:10.1016/S1470-2045(10)70233-3 · PMID 20965785

    100 patients stopped imatinib; of 69 followed a year or more, 42 (61%) relapsed, nearly all within 6 months, and all responded again on restarting. Non-randomized interim analysis.

  66. 66
    Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Blood · 2018 · 132(4):393-404doi:10.1182/blood-2016-09-739086 · PMID 29567798

    Five-year PACE results: cumulative arterial occlusive events rose to 31% in chronic phase; dose reductions began in October 2013. Single-arm; industry-sponsored.

  67. 67
    Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib.JAMA · 2014 · 311(4):353-4doi:10.1001/jama.2013.284531 · PMID 24449310

    Commentary on what the ponatinib safety episode taught about accelerated approval. Opinion; no abstract is indexed.

  68. 68
    Small S. Marketing and commercial distribution of ponatinib suspended following FDA request.Clin Adv Hematol Oncol · 2013 · 11(12):808-9PMID 25016626

    News item; no abstract or DOI indexed, and the claim rests on the title.

  69. 69
    Roth AJ. Reversing halt, FDA reauthorizes sale of ponatinib.Am J Manag Care · 2014 · 20(2 Spec No.):E11PMID 25764576

    News item; no abstract or DOI indexed, and the claim rests on the title.

  70. 70
    Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet · 2005 · 366(9496):1527-37doi:10.1016/S0140-6736(05)67625-8 · PMID 16257339

    ISEL, 1,692 patients, placebo-controlled: no significant survival gain overall (HR 0.89); benefit in preplanned subgroups of never-smokers and patients of Asian origin.

  71. 71
    Kazandjian D, Blumenthal GM, Yuan W, et al. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.Clin Cancer Res · 2016 · 22(6):1307-12doi:10.1158/1078-0432.CCR-15-2266 · PMID 26980062

    FDA staff summary: approval 13 July 2015 for exon 19 deletion or L858R tumors only, on a single-arm study of 106 patients (response 50%).

  72. 72
    Qian J, Xue X, Shannon J. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration.J Manag Care Spec Pharm · 2022 · 28(9):1046-1052doi:10.18553/jmcp.2022.28.9.1046 · PMID 36001100

    Records that on 9 September 2021 the FDA issued a drug safety communication and required revisions to the existing boxed warnings of tofacitinib, baricitinib and upadacitinib, and that the latter two had no comparable safety trial. The FDA notice itself, a primary regulatory document, was not opened. The analysis is of voluntary reports and is hypothesis-generating.

  73. 73
    Pamuk GE, Chow ECY, Ionan AC, et al. FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.Clin Cancer Res · 2024 · 30(19):4266-4271doi:10.1158/1078-0432.CCR-24-1086 · PMID 39088257

    The regulator's own summary, by FDA staff: accelerated approval 29 October 2021, converted 12 October 2022 on 96-week major molecular response 38% against 16%.

  74. 74
    Davids MS, Eyre TA, Woyach JA, et al. Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.Lancet · 2026 · 408(10553):453-470doi:10.1016/S0140-6736(26)01204-3 · PMID 42425121

    639 patients: adding a fixed course of pirtobrutinib to venetoclax-rituximab improved progression-free survival (HR 0.547; 24-month 87% versus 72%). Interim analysis; open-label; funded by Eli Lilly.

  75. 75
    Hunter T, Eckhart W. The discovery of tyrosine phosphorylation: it's all in the buffer!Cell · 2004 · 116(2 Suppl):S35-9doi:10.1016/s0092-8674(04)00049-2 · PMID 15055579

    The discoverers' own short history; no abstract indexed and text not opened. Its title, and the MeSH term Buffers, establish that the buffer story is their account.

  76. 76
    Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.N Engl J Med · 2013 · 369(1):32-42doi:10.1056/NEJMoa1215637 · PMID 23782158

    85 relapsed patients: response rate 71%, 26-month progression-free survival 75%. Single-arm; funded by Pharmacyclics and others.

  77. 77
    Yoshimasa Y, Seino S, Whittaker J, et al. Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing.Science · 1988 · 240(4853):784-7doi:10.1126/science.3283938 · PMID 3283938

    A single patient with type A insulin resistance and an insulin receptor point mutation at the proreceptor cleavage site. Case report with cell work.

  78. 78
    Kadowaki T, Bevins CL, Cama A, et al. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance.Science · 1988 · 240(4853):787-90doi:10.1126/science.2834824 · PMID 2834824

    One patient with leprechaunism, compound heterozygous for two insulin receptor mutations, one deleting the kinase domain.

  79. 79
    Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism.Proc Natl Acad Sci U S A · 1991 · 88(19):8696-9doi:10.1073/pnas.88.19.8696 · PMID 1717985

    One family: a glycine-to-arginine change at codon 664 in the KIT kinase domain, linked to dominant piebaldism.

  80. 80
    Pongdee T, Castells M, Akin C, et al. Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.World Allergy Organ J · 2026 · 19(4):101352doi:10.1016/j.waojou.2026.101352 · PMID 41867266

    Secondary analysis of the placebo-controlled PIONEER trial of a KIT D816V inhibitor: anaphylaxis in 4 of 141 on avapritinib and 3 of 71 on placebo. Too few events to conclude; coauthors employed by the manufacturer.

  81. 81
    Savarirayan R, Hoover-Fong J, Irving M, et al. Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.N Engl J Med · 2026 · 395(9):859-869doi:10.1056/NEJMoa2604565 · PMID 42370681

    PROPEL 3, 114 children, double-blind, placebo-controlled: height velocity 1.74 cm a year greater; body segment ratio unchanged. Funded by BridgeBio Pharma.

  82. 82
    Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.N Engl J Med · 2013 · 369(19):1783-96doi:10.1056/NEJMoa1306494 · PMID 24180494

    PACE, 449 heavily pretreated patients: major cytogenetic response in 70% of chronic-phase patients with T315I; serious arterial thrombotic events in 9% at 15 months. Single-arm; funded by Ariad.

  83. 83
    Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.N Engl J Med · 2012 · 366(9):799-807doi:10.1056/NEJMoa1110557 · PMID 22375971

    COMFORT-I, 309 patients: spleen volume down 35% or more in 41.9% versus 0.7%; 13 versus 24 deaths (HR 0.50, 95% CI 0.25-0.98). Funded by Incyte.

  84. 84
    Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.N Engl J Med · 2023 · 388(4):319-332doi:10.1056/NEJMoa2211582 · PMID 36511784

    ALPINE, 652 patients: zanubrutinib beat ibrutinib on progression-free survival (HR 0.65) with fewer cardiac events. Funded by BeiGene, the maker of zanubrutinib.

  85. 85
    Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.Lancet · 2021 · 397(10277):892-901doi:10.1016/S0140-6736(21)00224-5 · PMID 33676628

    First-in-human study of a reversible BTK inhibitor: response rate 62% in 121 CLL patients after covalent BTK inhibitors, 71% (17 of 24) with C481 mutations. Single-arm; funded by Loxo Oncology.

  86. 86
    Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.N Engl J Med · 2018 · 378(2):113-125doi:10.1056/NEJMoa1713137 · PMID 29151359

    FLAURA, 556 patients: progression-free survival 18.9 versus 10.2 months against gefitinib or erlotinib. Funded by AstraZeneca.

  87. 87
    Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer.N Engl J Med · 2006 · 355(26):2733-43doi:10.1056/NEJMoa064320 · PMID 17192538

    After trastuzumab, adding lapatinib lengthened time to progression from 4.4 to 8.4 months (HR 0.49). Interim analysis stopped early for benefit, which tends to overstate effects.

  88. 88
    Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer.N Engl J Med · 2014 · 371(21):1963-71doi:10.1056/NEJMoa1406766 · PMID 25264305

    50 patients: response rate 72%, median progression-free survival 19.2 months. Single-arm expansion cohort; funded by Pfizer and others.

  89. 89
    Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.N Engl J Med · 2020 · 383(9):813-824doi:10.1056/NEJMoa2005653 · PMID 32846060

    LIBRETTO-001: response 64% in 105 pretreated and 85% in 39 untreated patients; grade 3 or worse hypertension in 14%. Single-arm; funded by Loxo Oncology.

  90. 90
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med · 2002 · 347(7):472-80doi:10.1056/NEJMoa020461 · PMID 12181401

    147 patients randomized between two doses: partial response 53.7%, early resistance 13.6%. No untreated control arm.

  91. 91
    Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.N Engl J Med · 2017 · 377(5):454-464doi:10.1056/NEJMoa1614359 · PMID 28644114

    RATIFY: 3,277 screened, 717 randomized; overall survival hazard ratio 0.78 with midostaurin. Placebo-controlled; funded by the National Cancer Institute and Novartis.

  92. 92
    Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.N Engl J Med · 2019 · 381(18):1728-1740doi:10.1056/NEJMoa1902688 · PMID 31665578

    ADMIRAL, 371 patients: median survival 9.3 versus 5.6 months (HR 0.64). Open-label; funded by Astellas.

  93. 93
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma.N Engl J Med · 2008 · 359(4):378-90doi:10.1056/NEJMoa0708857 · PMID 18650514

    SHARP, 602 patients, placebo-controlled: median survival 10.7 versus 7.9 months (HR 0.69); 2% partial responses.

  94. 94
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med · 2007 · 356(2):115-24doi:10.1056/NEJMoa065044 · PMID 17215529

    750 patients: progression-free survival 11 versus 5 months (HR 0.42).

  95. 95
    Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.N Engl J Med · 2018 · 378(8):731-739doi:10.1056/NEJMoa1714448 · PMID 29466156

    Pooled single-arm studies, 55 patients with 17 tumor types: response 75% by independent review. Funded by Loxo Oncology and others.

  96. 96
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Engl J Med · 2001 · 344(14):1038-42doi:10.1056/NEJM200104053441402 · PMID 11287973

    Dose-escalating pilot, 58 patients, no control arm: responses in 55% with myeloid blast crisis and 70% with lymphoid disease, nearly all of whom relapsed.

  97. 97
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.N Engl J Med · 2001 · 344(14):1052-6doi:10.1056/NEJM200104053441404 · PMID 11287975

    A single-patient report, published the same day as the phase 1 CML trial. No abstract is indexed.

  98. 98
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med · 2003 · 348(11):994-1004doi:10.1056/NEJMoa022457 · PMID 12637609

    IRIS, 1,106 patients: major cytogenetic response at 18 months 87.1% versus 34.7%. Open-label, with crossover allowed; sponsored by Novartis.

  99. 99
    Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.Proc Natl Acad Sci U S A · 2008 · 105(6):2070-5doi:10.1073/pnas.0709662105 · PMID 18227510

    Binding and crystal studies: T790M mutants still bind gefitinib with low-nanomolar affinity; a more than tenfold rise in ATP affinity is the main mechanism of resistance, overturning the steric explanation.

  100. 100
    Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial.Blood · 2021 · 138(21):2042-2050doi:10.1182/blood.2021012082 · PMID 34407543

    OPTIC, 283 patients randomized to 45, 30 or 15 mg: response at 12 months 44.1%, 29.0% and 23.1%; best balance with 45 mg reduced to 15 mg on response. Open-label; sponsor-employed coauthors.

  101. 101
    Hanley MJ, Diderichsen P, Rich B, et al. Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.Clin Pharmacol Ther · 2023 · 114(2):413-422doi:10.1002/cpt.2956 · PMID 37219378

    Modeling of OPTIC: ponatinib exposure predicted arterial occlusive events, hazard ratio 2.05 per 15-mg dose increase. A model, not a new trial; written by the manufacturer's scientists and contractors.

  102. 102
    Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.Blood · 2021 · 138(21):2031-2041doi:10.1182/blood.2020009984 · PMID 34407542

    ASCEMBL, 233 patients after two or more TKIs: major molecular response at week 24, 25.5% versus 13.2%. Open-label; Novartis-employed coauthors.

  103. 103
    Han JJ, Lee JO, Kim KH, et al. Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review.Blood Res · 2026 · 61(1)doi:10.1007/s44313-026-00153-2 · PMID 42458108

    Systematic review to December 2025 reporting ASC4FIRST at 96 weeks (major molecular response 74.1% versus 52.0%) and its safety signals. Secondary summary; the 96-week primary report was not opened.

  104. 104
    Kawaguchi K, Maeda A, Mizuno I, Murayama T. [Lymphoid blast crisis in chronic myeloid leukemia after long-term treatment-free remission following imatinib treatment].Rinsho Ketsueki · 2026 · 67(4):299-302doi:10.11406/rinketsu.67.299 · PMID 42128858

    A single case, in Japanese with an English abstract: a man who relapsed years after stopping imatinib, declined to restart, and developed lymphoid blast crisis. One case shows what can happen, not how often.

  105. 105
    Apperley JF, Milojkovic D, Cross NCP, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia.Leukemia · 2025 · 39(8):1797-1813doi:10.1038/s41375-025-02664-w · PMID 40646132

    The current international guideline: most patients will remain on treatment for many years; dose reduction rather than switching for side effects.

  106. 106
    Jänne PA, Planchard D, Kobayashi K, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J Med · 2026 · 394(1):27-38 (online 2025)doi:10.1056/NEJMoa2510308 · PMID 41104938

    FLAURA2 final survival, 557 patients: 47.5 versus 37.6 months, HR 0.77, at the cost of grade 3 or worse adverse events in 70% versus 34%. Open-label; funded by AstraZeneca.

  107. 107
    Shaw AT, Solomon BJ, Felip E, et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.Ann Oncol · 2026 · 37(9):1242-1252doi:10.1016/j.annonc.2026.05.692 · PMID 42217582

    CROWN, 296 patients: 7-year progression-free survival 55% against 3% (HR 0.19); post hoc; overall survival immature. Pfizer-employed coauthors.

  108. 108
    Heymach JV, Ruiter G, Ahn MJ, et al. Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.N Engl J Med · 2025 · 392(23):2321-2333doi:10.1056/NEJMoa2503704 · PMID 40293180

    Beamion LUNG-1 phase 1a-1b, cohort 1: confirmed response in 71% of 75 at 120 mg. Funded by Boehringer Ingelheim.

  109. 109
    Heymach JV, Yamamoto N, Girard N, et al. First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.N Engl J Med · 2026 · 394(17):1675-1684doi:10.1056/NEJMoa2516969 · PMID 41985129

    Single-arm cohort of 74 untreated patients: confirmed response 76%. Funded by Boehringer Ingelheim.

  110. 110
    Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.N Engl J Med · 2015 · 373(25):2425-37doi:10.1056/NEJMoa1509388 · PMID 26639149

    RESONATE-2, 269 patients aged 65 or older: progression and death both reduced (HR 0.16 each) against chlorambucil. Open-label; funded by Pharmacyclics and others.

  111. 111
    Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.Lancet · 2005 · 365(9464):1054-61doi:10.1016/S0140-6736(05)71142-9 · PMID 15781101

    With allele-specific PCR, V617F in 71 of 73 (97%) with polycythemia vera, 29 of 51 (57%) with essential thrombocythemia and 8 of 16 (50%) with myelofibrosis.

  112. 112
    Misra DP, Pande G, Agarwal V. Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box.Clin Rheumatol · 2023 · 42(2):621-632 (online 2022)doi:10.1007/s10067-022-06415-5 · PMID 36264400

    Review arguing the excess risk concentrates in patients with prior cardiovascular disease or risk factors, and that evidence was insufficient to extend it to baricitinib and upadacitinib. A narrative review.

  113. 113
    Ingrassia JP, Maqsood MH, Gelfand JM, et al. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.JAMA Dermatol · 2024 · 160(1):28-36doi:10.1001/jamadermatol.2023.4090 · PMID 37910098

    35 trials, 20,651 skin-disease patients, mean follow-up 4.9 months: no significant increase in heart events plus death (OR 0.83) or clots (OR 0.52). Follow-up far shorter than ORAL Surveillance's four years.

  114. 114
    Benandi K, Spires A, Hansen A, Linfante A. Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network.J Am Acad Dermatol · 2025 · 93(4):1035-1041doi:10.1016/j.jaad.2025.06.058 · PMID 40794004

    Retrospective records study: topical ruxolitinib, which carries the class boxed warning, had fewer arterial clots and tuberculosis cases than oral JAK inhibitors. Observational; no survival analysis.

  115. 115
    Smolen JS, Edwards CJ, Konzett V, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.Ann Rheum Dis · 2026 · 85(6):991-1009doi:10.1016/j.ard.2026.01.023 · PMID 41826212

    The current European guideline; a consensus document. JAK inhibitors may be considered after careful consideration of cardiovascular, cancer and clotting risks.

  116. 116
    Laskou F, Konzett V, Smolen JS, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis.Ann Rheum Dis · 2026 · 85(6):1055-1072doi:10.1016/j.ard.2026.02.024 · PMID 41951459

    71 studies, January 2022 to January 2025, mostly observational and many claims-based: no consistent excess of major heart events with JAK inhibitors against biologics; more venous clots and shingles; tuberculosis not increased.

  117. 117
    Fatima F, Mirza A, Bhatti MI, Hussain F, Shahzad Z. Pirtobrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Systematic Review.Am J Clin Oncol · 2026doi:10.1097/COC.0000000000001363 · PMID 42594294

    Narrative synthesis of three phase 3 trials (CLL-321, CLL-313, CLL-314) to July 2026: consistent progression-free benefit, overall survival called inconclusive because of crossover, less atrial fibrillation than ibrutinib. A secondary summary; the three primary reports are cited directly as [117], [118] and [119].

  118. 118
    Wang E, Mi X, Thompson MC, et al. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.N Engl J Med · 2022 · 386(8):735-743doi:10.1056/NEJMoa2114110 · PMID 35196427

    9 of 55 pirtobrutinib-treated patients with acquired genetic resistance: BTK kinase-domain or PLCG2 mutations, some also resistant to covalent inhibitors. Genomic and laboratory work; some coauthors from Loxo Oncology at Lilly.

  119. 119
    Sharman JP, Munir T, Grosicki S, et al. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).J Clin Oncol · 2025 · 43(22):2538-2549doi:10.1200/JCO-25-00166 · PMID 40479620

    BRUIN CLL-321, 238 patients, open-label: progression-free survival HR 0.54; overall survival HR 1.09 (0.68-1.75). Eli Lilly employees among the authors. Two errata have been published (PubMed 40577663 and 40729625); their content was not indexed.

  120. 120
    Jurczak W, Kwiatek M, Czyz J, et al. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.J Clin Oncol · 2026 · 44(6):466-475 (online 2025)doi:10.1200/JCO-25-02380 · PMID 41363773

    BRUIN CLL-313, 282 patients, open-label: progression-free survival HR 0.199; interim overall survival HR 0.257 despite 52.9% effective crossover. Eli Lilly employees among the authors.

  121. 121
    Woyach JA, Qiu L, Grosicki S, et al. Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.J Clin Oncol · 2026 · 44(6):476-485 (online 2025)doi:10.1200/JCO-25-02477 · PMID 41353787

    BRUIN CLL-314, 662 patients: response rate noninferior, 87.0% against 78.5%; less atrial fibrillation and hypertension. Eli Lilly employees among the authors.

  122. 122
    Fox RJ, Bar-Or A, Traboulsee A, et al. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.N Engl J Med · 2025 · 392(19):1883-1892doi:10.1056/NEJMoa2415988 · PMID 40202696

    HERCULES, 1,131 participants, double-blind: 6-month confirmed disability progression 22.6% against 30.7% (HR 0.69); ALT above 3 times normal in 4.0% against 1.6%. Funded by Sanofi.

  123. 123
    Lambe J, Fox RJ. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis.Drugs · 2026 · 86(7):989-1012doi:10.1007/s40265-026-02324-y · PMID 42126690

    Review of phase 2 and 3 trials; notes liver enzyme elevations that can reach life-threatening levels.

  124. 124
    Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.Lancet · 2007 · 370(9604):2011-9doi:10.1016/S0140-6736(07)61865-0 · PMID 18083403

    Retrospective review of 75 GIST patients on sunitinib: cardiovascular events in 11%, heart failure in 8%, hypertension above 150/100 in 47%.

  125. 125
    Liu WH, Cheng YJ, Kang J, et al. Cardiovascular adverse events in non-small cell lung cancer patients receiving osimertinib therapy: a systematic review and meta-analysis.Lung Cancer · 2026 · 217:109413doi:10.1016/j.lungcan.2026.109413 · PMID 42229338

    61 studies, 10,316 patients: hypertension the commonest cardiovascular event; QTc prolongation 6.88%; higher with added chemotherapy. Pooled incidences, mostly without control arms.

  126. 126
    Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).Eur Heart J · 2022 · 43(41):4229-4361doi:10.1093/eurheartj/ehac244 · PMID 36017568

    The current European guideline on monitoring the heart during cancer treatment, covering QTc prolongation, hypertension and VEGF inhibitors among others. No abstract is indexed.

  127. 127
    Oba T, Chino T, Soma A, et al. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.Endocr J · 2020 · 67(12):1215-1226doi:10.1507/endocrj.EJ20-0171 · PMID 32814730

    34 studies: each TKI had its own signature toxicity, QTc prolongation for vandetanib, hypertension and proteinuria for lenvatinib, hand-foot syndrome for sorafenib.

  128. 128
    Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy.Blood · 2007 · 110(4):1233-7doi:10.1182/blood-2007-01-070144 · PMID 17449798

    Review of reported serious cardiac events among 1,276 patients in imatinib trials: 22 (1.7%) with heart failure symptoms, 8 (0.6%) possibly or probably drug-related. Retrospective.

  129. 129
    Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib.Circulation · 2012 · 125(17):2128-37doi:10.1161/CIRCULATIONAHA.111.079921 · PMID 22451584

    Nine cases in the French registry; lowest estimated incidence 0.45% of exposed patients; most improved but did not fully recover after stopping.

  130. 130
    Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.Leukemia · 2021 · 35(2):440-453doi:10.1038/s41375-020-01111-2 · PMID 33414482

    Randomized: deeper molecular responses and more cardiovascular events with nilotinib (16.5% and 23.5% against 3.6%), similar 10-year survival. Novartis-employed coauthors.

  131. 131
    Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.Blood · 2013 · 121(22):4439-42doi:10.1182/blood-2013-03-490003 · PMID 23620577

    A statement by more than 100 CML specialists against TKI prices. Opinion, not cost data.

  132. 132
    Cole AL, Dusetzina SB. Generic Price Competition For Specialty Drugs: Too Little, Too Late?Health Aff (Millwood) · 2018 · 37(5):738-742doi:10.1377/hlthaff.2017.1684 · PMID 29733710

    US claims data on generic imatinib: few entrants, smaller-than-expected price falls, prescribing shifted to brand-name drugs.

  133. 133
    Marsman T, van Straaten W, Koolman X. Prices and prescribing of competing cancer medicines in Dutch hospitals after imatinib loss of exclusivity: a retrospective claims analysis.Health Policy · 2026 · 174:105775doi:10.1016/j.healthpol.2026.105775 · PMID 42804841

    National claims 2013-2022: imatinib spending down 95% after 2017; patented alternatives showed little or no price convergence. One author affiliated with a Dutch insurer.

  134. 134
    Vaughn JE, Zawadzki N, Zhang S, et al. Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives.Clinicoecon Outcomes Res · 2026 · 18:626752doi:10.2147/CEOR.S626752 · PMID 42445105

    US model from label dosing and wholesale acquisition costs: 2025 per-patient-year cost about $22,430 for imatinib, $72,693 for dasatinib, $89,138 for nilotinib, over $100,000 for the others. Two authors employed by Novartis; others by a consultancy.

  135. 135
    Haddad FG, Jabbour E, Breccia M, et al. SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia-How to Define the Treatment Value?Clin Lymphoma Myeloma Leuk · 2026 · 26(2):57-65 (online 2025)doi:10.1016/j.clml.2025.10.001 · PMID 41139562

    Expert review: generic imatinib under $1,000 a year worldwide; second-generation drugs, even generics, still too expensive in the United States for good treatment value. Opinion, not price data.

  136. 136
    Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance.Physiol Rev · 2018 · 98(4):2133-2223doi:10.1152/physrev.00063.2017 · PMID 30067154

    Review weighing the evidence for and against proposed mediators of insulin resistance: bioactive lipids, endoplasmic reticulum and mitochondrial stress, inflammatory and other circulating factors.

  137. 137
    Gitelman SE, Bundy BN, Ferrannini E, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Diabetes Endocrinol · 2021 · 9(8):502-514doi:10.1016/S2213-8587(21)00139-X · PMID 34214479

    67 adults: 26 weeks of imatinib preserved insulin output slightly at 12 months (one-tailed p = 0.048), not sustained at 24 months.

  138. 138
    Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements.J Nutr · 2001 · 131(4 Suppl):1362S-75Sdoi:10.1093/jn/131.4.1362S · PMID 11285356

    Pharmacokinetics in 19 women, and an analysis of 33 phytoestrogen supplements whose isoflavone content differed considerably from the label.

  139. 139
    Wang Z, Jones G, Winzenberg T, et al. Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis: A Randomized Trial.Ann Intern Med · 2020 · 173(11):861-869doi:10.7326/M20-0990 · PMID 32926799

    70 participants, 12 weeks, double-blind: knee pain improved by 9.1 mm on a visual scale; effusion-synovitis and cartilage unchanged. Co-funded by Natural Remedies Private Limited.

  140. 140
    Shanafelt TD, Call TG, Zent CS, et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.J Clin Oncol · 2009 · 27(23):3808-14doi:10.1200/JCO.2008.21.1284 · PMID 19470922

    33 early CLL patients on a standardized green tea catechin preparation: one partial remission, lymphocyte counts down at least 20% in a third, mild liver enzyme rises in a third. Phase 1, no control group.

  141. 141
    Shanafelt TD, Call TG, Zent CS, et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.Cancer · 2013 · 119(2):363-70 (online 2012)doi:10.1002/cncr.27719 · PMID 22760587

    Single-arm, 42 patients at 2,000 mg twice daily: sustained lymphocyte fall of at least 20% in 31%; lymph nodes halved in 20 of 29.

  142. 142
    Dostal AM, Samavat H, Bedell S, et al. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial.Food Chem Toxicol · 2015 · 83:26-35doi:10.1016/j.fct.2015.05.019 · PMID 26051348

    Randomized, double-blind, 1,075 women: ALT elevation in 6.7% on extract against 0.7% on placebo; 1.3% had ALT-related serious adverse events.

  143. 143
    Acosta L, Byham-Gray L, Kurzer M, Samavat H. Hepatotoxicity with High-Dose Green Tea Extract: Effect of COMT and UGT1A4 Genotypes.J Diet Suppl · 2023 · 20(6):850-869 (online 2022)doi:10.1080/19390211.2022.2128501 · PMID 36178169

    Secondary analysis of the Minnesota Green Tea Trial (1,075 women; 843 mg EGCG a day for a year): ALT rose about 80% by months 6-9 in one genotype group. Post hoc genetic subgroups. The PubMed record drops the italic gene symbols from the title and abstract; they are restored here from its keywords and the variant numbers given (rs4680, rs6755571).

  144. 144
    Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.EBioMedicine · 2019 · 40:554-563doi:10.1016/j.ebiom.2018.12.052 · PMID 30616998

    Dasatinib plus quercetin in 14 patients, open-label, three weeks: walking tests improved, lung function did not change. A feasibility pilot, not proof of benefit.

  145. 145
    Farr JN, Atkinson EJ, Achenbach SJ, et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial.Nat Med · 2024 · 30(9):2605-2612doi:10.1038/s41591-024-03096-2 · PMID 38956196

    60 women: the primary end point, change in the bone resorption marker CTx at 20 weeks, did not differ; P1NP rose transiently; exploratory high-senescence subgroup.

  146. 146
    Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions.Nat Rev Drug Discov · 2021 · 20(7):551-569doi:10.1038/s41573-021-00195-4 · PMID 34002056

    Review: more than 70 kinase drugs approved since imatinib in 2001. One author was an AstraZeneca employee.

  147. 147
    Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.J Clin Invest · 2011 · 121(1):396-409 (online 2010)doi:10.1172/JCI35721 · PMID 21157039

    Laboratory work on patient cells: primitive CML stem cells survived with cytokine support although imatinib fully inhibited BCR-ABL.

  148. 148
    Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.N Engl J Med · 2007 · 356(5):459-68doi:10.1056/NEJMoa065202 · PMID 17267906

    Four gain-of-function JAK2 exon 12 mutations in 10 V617F-negative patients; patient samples, cell and mouse work.

This is education, not medical advice. Nothing on this page is written with knowledge of your history, your medications or your risks, and nothing here is a dose. Do not start or stop any treatment on the basis of it — talk to your own physician. Read the full medical disclaimer.

The letter

Every source, in your inbox.

The full citation list for each investigation, the studies that didn't make the episode, and any corrections — sent the morning it publishes.

No sponsors · No supplement affiliates · Unsubscribe any time